------------------------------
OMB APPROVAL
-------------------------------
UNITED STATES OMB Number: 3235-0145
SECURITIES AND EXCHANGE COMMISSION Expires: October 31, 1994
Washington, D.C. 20549 Estimated average burden
hours per form..........14.90
-------------------------------
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. _______________)*
AVECOR CARDIOVASCULAR INC.
(Name of Issuer)
Common Stock, $.01 par value
(Title of Class of Securities)
53547 10 5
(CUSIP Number)
Carol E. Malkinson, Esq.
Medtronic, Inc.
7000 Central Ave. N.E.
Minneapolis, Minnesota 55432
(612)514-4000
(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)
July 12, 1998
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box |_|.
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
<PAGE>
CUSIP No. 292962 10 7
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Medtronic, Inc.
41-0793183
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) |_|
(b) |_|
3 SEC USE ONLY
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
WC
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) |_|
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Minnesota
7 SOLE VOTING POWER
1,947,811 (1)
NUMBER OF
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 1,124,499 (1)
OWNED BY
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 1,947,811 (1)
PERSON
WITH 10 SHARED DISPOSITIVE POWER
0
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,072,310 (includes 1,600,851 shares which are subject to the Stock
Option Agreement and 1,124,499 shares which are subject to the
Agreements to Facilitate Merger)(1)
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|_|
(SEE INSTRUCTIONS)
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
31.74%(1)
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
HC
1 346,960 of the shares of Common Stock of AVECOR Cardiovascular Inc. ("AVECOR")
covered by this Statement are owned by Medtronic Asset Management, Inc.
("MAMI"), a wholly owned subsidiary of Medtronic, Inc. ("Medtronic"). 1,600,851
of the additional shares of Common Stock of AVECOR covered by this Statement are
subject to a Stock Option Agreement dated July 12, 1998 and 1,124,499 of the
additional shares of Common Stock of AVECOR covered by this Statement are
subject to Agreements to Facilitate Merger dated on or after such date, and
described in Item 3 of this Statement. Nothing herein shall be deemed to be an
admission by Medtronic as to the beneficial ownership of any of such shares of
AVECOR that are subject to the Stock Option Agreement or the Agreements to
Facilitate Merger, and Medtronic hereby disclaims beneficial ownership of all
such shares of AVECOR so subject.
<PAGE>
CUSIP No. 292962 10 7
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Medtronic Asset Management, Inc.
41-1721127
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) |_|
(b) |_|
3 SEC USE ONLY
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
AF
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) |_|
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Minnesota
7 SOLE VOTING POWER
346,960
NUMBER OF
SHARES 8 SHARED VOTING POWER
BENEFICIALLY 0
OWNED BY
EACH 9 SOLE DISPOSITIVE POWER
REPORTING 346,960
PERSON
WITH 10 SHARED DISPOSITIVE POWER
0
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
346,960
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|_|
(SEE INSTRUCTIONS)
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4.32%
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
<PAGE>
Item 1. Security and Issuer
The class of equity security to which this statement relates is the Common
Stock, $.01 par value, of AVECOR Cardiovascular Inc. ("AVECOR"). The name and
address of the principal executive offices of the issuer of such securities are
AVECOR Cardiovascular Inc., 7611 Northland Drive North, Minneapolis, MN 55428.
Item 2. Identity and Background
(a), (b) and (c)
Medtronic, Inc., 7000 Central Ave. N.E., Minneapolis, Minnesota 55432, is a
Minnesota corporation ("Medtronic"), principally engaged in the business of
therapeutic medical technology, specializing in implantable and interventional
therapies. Medtronic Asset Management, Inc., 7000 Central Ave. N.E.,
Minneapolis, Minnesota 55432, a Minnesota corporation ("MAMI"), is a
wholly-owned subsidiary of Medtronic through which Medtronic holds certain
investments. Information is provided below with respect to persons who are
directors and executive officers of the reporting persons.
William W. George, Chairman, Chief Executive Officer and Director, Medtronic,
Inc., 7000 Central Avenue N.E., Minneapolis, MN 55432;
Arthur D. Collins, Jr., President, Chief Operating Officer and Director,
Medtronic, Inc., and President and Director, MAMI, 7000 Central Avenue N.E.,
Minneapolis, MN 55432;
Glen D. Nelson, M.D., Vice Chairman and Director, Medtronic, Inc., 7000 Central
Avenue N.E., Minneapolis, MN 55432;
William R. Brody, M.D., Ph.D., Director, Medtronic, Inc., President, The Johns
Hopkins University, 3400 North St. Charles St., 242 Garland Hall,
Baltimore, MD 21218;
Paul W. Chellgren, Director, Medtronic, Inc., Chairman and Chief Executive
Officer, Ashland, Inc., 1000 Ashland Drive, Russell, KY 41114;
Antonio M. Gotto, Jr., M.D., Director, Medtronic, Inc., Dean, Cornell University
Medical College, Medical Affairs Provost, Cornell University Office of the Dean,
1300 York Avenue, New York, NY 10021;
Bernadine P. Healy, M.D., Director, Medtronic, Inc., Dean, College of Medicine,
Ohio State University, 254 Meiling Hall, 370 W. 9th Avenue, Columbus, OH
43210;
Thomas E. Holloran, Director, Medtronic, Inc., Professor, Graduate School of
Business, University of St. Thomas, 1000 LaSalle Avenue - Suite 343,
Minneapolis, MN 55403-2005;
Richard L. Schall, Director, Medtronic, Inc., Consultant, 4900 IDS Center,
80 South 8th Street, Minneapolis, MN 55402;
Jack W. Schuler, Director, Medtronic, Inc., Chairman, Stericycle, Inc.
and Ventana Medical Systems, Inc., 1419 Lake Cook Road, Suite 410,
Deerfield, IL 60015;
Gerald W. Simonson, Director, Medtronic, Inc., President and Chief Executive
Officer, Omnetics Connector Corporation, 7260 Commerce Circle East,
Fridley, MN 55432;
Gordon M. Sprenger, Director, Medtronic, Inc., Executive Officer,
Allina Health System, 5601 Smetana Drive, Minneapolis, MN 55440;
Richard A. Swalin, Ph.D., Director, Medtronic, Inc., Professor Emeritus,
The University of Arizona, 4715 East Fort Lowell Road, Tucson, AZ 85712;
Bobby I. Griffin, Executive Vice President, Medtronic, Inc., 7000 Central
Avenue N.E., Minneapolis, MN 55432;
Bill K. Erickson, Senior Vice President and President, Americas, Medtronic,
Inc., 7000 Central Avenue N.E., Minneapolis, MN 55432;
Janet S. Fiola, Senior Vice President, Human Resources, Medtronic, Inc.,
7000 Central Avenue N.E., Minneapolis, MN 55432;
B. Kristine Johnson, Senior Vice President and Chief Administrative Officer,
Medtronic, Inc., 7000 Central Avenue N.E., Minneapolis, MN 55432;
Philip M. Laughlin, Senior Vice President and President, Cardiac Surgery,
Medtronic, Inc., 7000 Central Avenue N.E., Minneapolis, MN 55432;
Ronald E. Lund, Senior Vice President, General Counsel and Secretary, Medtronic,
Inc., and Vice President, Secretary and Director, MAMI, 7000 Central Avenue
N.E., Minneapolis, MN 55432;
Stephen H. Mahle, Senior Vice President and President, Cardiac Rhythm
Management, Medtronic, Inc., 7000 Central Avenue N.E., Minneapolis, MN 55432;
John A. Meslow, Senior Vice President and President, Neurological, Medtronic,
Inc., 7000 Central Avenue N.E., Minneapolis, MN 55432;
Robert L. Ryan, Senior Vice President and Chief Financial Officer, Medtronic,
Inc., and Chief Financial Officer and Director, MAMI, 7000 Central Avenue N.E.,
Minneapolis, MN 55432;
Barry Wilson, Senior Vice President and President, Europe, Middle East
and Africa, Medtronic, Inc., 7000 Central Avenue N.E., Minneapolis, MN 55432.
<PAGE>
(d) and (e)
To the knowledge of the reporting persons, neither reporting person nor any of
the persons listed above has, during the last five years, been convicted in a
criminal proceeding or was, during the last five years, a party to a civil
proceeding as a result of which such person was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws.
(f) All of the individuals referred to above are United States citizens, except
Mr. Wilson, who is a dual citizen of the United Kingdom and South Africa.
Item 3. Source and Amount of Funds or Other Consideration
This Statement relates to the execution of a certain Stock Option Agreement
dated July 12, 1998, between AVECOR and Medtronic (the "Stock Option Agreement")
and to the execution or future execution of certain Agreements to Facilitate
Merger (the "Agreements to Facilitate Merger") between Medtronic and each of the
following AVECOR shareholders: Anthony Badolato, Allan R. Seck, Gregory J.
Melsen, David W. Stassen, Edward E. Strickland, J. Gordon Wright and William S.
Haworth. The Stock Option Agreement and the Agreements to Facilitate Merger are
intended as an inducement to Medtronic to enter into and proceed with the
Agreement and Plan of Merger (the "Merger Agreement"), dated July 12, 1998,
among Medtronic, AVECOR and AC Merger Corp. ("Merger Subsidiary"), a wholly
owned subsidiary of Medtronic. Pursuant to the Merger Agreement and subject to
the conditions set forth therein, Merger Subsidiary will merge with and into
AVECOR (the "Merger"), and each issued and outstanding share of Common Stock of
AVECOR will be converted into the right to receive a fraction of a share of
Medtronic Common Stock, par value $.10 per share, which fraction will equal
$11.125 divided by the average of the closing sale prices for Medtronic Common
Stock during the 18 trading days ending on and including the second trading day
immediately preceding the effective time of the Merger.
Pursuant to the Stock Option Agreement, AVECOR granted Medtronic the right to
purchase at an exercise price of $11.125 per share 1,600,851 shares of AVECOR
Common Stock, which was represented in the Merger Agreement to reflect
approximately 19.9% of the AVECOR Common Stock outstanding on the date of the
Stock Option Agreement's execution. The Stock Option Agreement is not
exercisable until and unless the earlier of certain events specified therein,
including, but not limited to, the termination of the Merger Agreement under
certain circumstances. If the Stock Option Agreement becomes exercisable, any
shares purchased pursuant to the exercise of the Stock Option Agreement would be
made with funds from Medtronic's working capital. If the Stock Option Agreement
becomes exercisable, under certain circumstances, Medtronic can, in lieu of
exercising the Stock Option Agreement, put such Agreement to AVECOR and receive
a cancellation payment from AVECOR in cash therefor.
Pursuant to the Agreements to Facilitate Merger, each of the persons noted above
has agreed or will agree to vote all or, in certain cases, a portion of such
person's AVECOR shares that such person has power to vote in favor of approval
of the Merger Agreement and the Merger, and against any other action that would
impede or discourage the Merger. Medtronic may hereafter enter into similar
Agreements to Facilitate Merger with other holders of AVECOR Common Stock.
Copies of the Stock Option Agreement, the form of the Agreement to Facilitate
Merger and the Merger Agreement are included as Exhibits to this Statement and
are incorporated herein by reference. The foregoing description of such
Agreements is qualified in its entirety by reference to such Exhibits.
This Statement also relates to 346,960 shares of AVECOR Common Stock
beneficially owned by the reporting persons which were acquired earlier in 1998
in open market purchases with funds from working capital.
Item 4. Purpose of Transaction
The purpose of the recent transactions described in Item 3 is to facilitate
approval and consummation of the Merger. Other than in connection with the
Merger described above, the reporting persons have no plans or proposals which
relate to or would result in any of the matters listed in paragraphs (a) through
(j) of Item 4 of Schedule 13D.
Item 5. Interest in Securities of the Issuer
(a) and (b) Medtronic, through MAMI, is the beneficial owner of 346,960 shares
of the Common Stock of AVECOR. As a result of the Stock Option Agreement,
Medtronic may be deemed to be the beneficial owner of 1,600,851 additional
shares of Common Stock of AVECOR covered by such Stock Option Agreement. As a
result of the Agreements to Facilitate Merger, Medtronic may be deemed to be the
beneficial owner of 1,124,499 shares of Common Stock of AVECOR covered by such
Agreements. Such 3,072,310 shares (including those beneficially owned by
Medtronic, those covered by the Stock Option Agreement and those covered by
Agreements to Facilitate Merger) would represent approximately 31.74% of the
shares of AVECOR (based on the number of shares of AVECOR Common Stock
outstanding on June 30, 1998, as represented to Medtronic by AVECOR). Nothing
herein, however, shall be deemed to be an admission by Medtronic or MAMI that
either reporting person is the beneficial owner of any of the shares covered by
the Stock Option Agreement or the Agreements to Facilitate Merger, and Medtronic
and MAMI hereby disclaim beneficial ownership of all shares covered by such
Agreements. To the knowledge of the reporting persons, no other person named in
Item 2 beneficially owns any AVECOR shares.
(c) To the knowledge of the reporting persons, the only transactions in the
Common Stock of AVECOR by any person named in paragraph (a) above during the
past 60 days are the Stock Option Agreement and Agreements to Facilitate Merger
reported in Item 3 above.
(d) No other person (other than the AVECOR shareholder who has signed an
Agreement to Facilitate Merger in the case of the shares covered by such
shareholder's Agreement to Facilitate Merger) is known to have the right to
receive or the power to direct the receipt of dividends from, or the proceeds of
the sale of, the subject securities.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect
to Securities of the Issuer.
See Item 3 for a description of the Stock Option Agreement, Agreements to
Facilitate Merger and Merger Agreement.
Item 7. Material to Be Filed as Exhibits
Exhibit A - Agreement as to Joint Filing
Exhibit B - Stock Option Agreement
Exhibit C - Form of Agreement to Facilitate Merger
Exhibit D - Agreement and Plan of Merger
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Date: July 21, 1998
MEDTRONIC, INC.
By: /s/ Ronald E. Lund
Its: Senior Vice President,
General Counsel and Secretary
MEDTRONIC ASSET MANAGEMENT, INC.
By: /s/ Ronald E. Lund
Its: Vice President and Secretary
<PAGE>
EXHIBIT INDEX
Exhibit Description
A Agreement as to Joint Filing
B Stock Option Agreement
C Form of Agreement to Facilitate Merger
D Agreement and Plan of Merger
EXHIBIT A
The undersigned hereby agree to file a joint Schedule 13D with respect to
the interests of the undersigned in AVECOR Cardiovascular Inc. and that the
Schedule 13D to which this Exhibit A is attached has been filed on behalf of
each of the undersigned.
Dated: July 21, 1998 MEDTRONIC, INC.
By: /s/ Ronald E. Lund
Its: Senior Vice President,
Legal Counsel and Secretary
MEDTRONIC ASSET MANAGEMENT, INC.
By: /s/ Ronald E. Lund
Its: Vice President and Secretary
Exhibit B
STOCK OPTION AGREEMENT
THIS AGREEMENT is dated as of July 12, 1998, between Medtronic, Inc., a
Minnesota corporation ("Grantee"), and AVECOR Cardiovascular, Inc., a Minnesota
corporation ("Issuer").
RECITALS
A. Grantee, Issuer, and AC Merger Corp., a Minnesota corporation and
wholly-owned subsidiary of Grantee ("Merger Subsidiary"), are entering into an
Agreement and Plan of Merger (the "Merger Agreement") which provides, among
other things, that, upon the terms and subject to the conditions thereof, Merger
Subsidiary will be merged with and into Issuer (the "Merger").
B. Prior to the execution and delivery of this Agreement, certain
directors and officers of Issuer have, to induce Grantee to execute the Merger
Agreement, executed and delivered to Grantee the Agreements to Facilitate Merger
described in the Merger Agreement.
C. As a further and subsequent inducement to have Grantee enter into
the Merger Agreement, Grantee has required that Issuer enter into this
Agreement, which provides, among other things, that Issuer grant to Grantee an
option to purchase shares of Issuer's Common Stock, par value $.0l per share
("Issuer Common Stock"), upon the terms and subject to the conditions provided
for herein.
NOW, THEREFORE, in consideration of the premises and mutual covenants
and agreements contained in this Agreement and the Merger Agreement, the parties
agree as follows:
1. Grant of Option. Subject to the terms and conditions of this
Agreement, Issuer hereby grants to Grantee an irrevocable option (the "Option")
to purchase 1,600,851 shares of Issuer Common Stock (the "Option Shares"), in
the manner set forth below, at an exercise price of $11.125 per share of Issuer
Common Stock, subject to adjustment as provided below (the "Option Price").
Issuer represents that the Option Shares represent at least 19.9% of the number
of shares of Issuer Common Stock outstanding on the date hereof. Capitalized
terms used herein but not defined herein shall have the meanings set forth in
the Merger Agreement.
<PAGE>
2. Exercise of option.
(a) Subject to the satisfaction or waiver of the conditions
set forth in Section 9 of this Agreement, prior to the termination or
expiration of this Agreement in accordance with its terms, Grantee or
its designee (which shall be a wholly-owned subsidiary of Grantee) may
exercise the option, in whole or in part, at any time or from time to
time on or after the public disclosure of, or the time at which Grantee
shall have learned of, the earliest of (i) or (ii) below to occur:
(i) the Merger Agreement is terminated pursuant to
Section 7.1(e) of the Merger Agreement and within 12 months
after termination of the Merger Agreement the Issuer enters
into an agreement providing for an Alternative Proposal, or
the Merger Agreement is terminated pursuant to 7.1(f) of the
Merger Agreement; or
(ii) any third party makes an Alternative Proposal to
which the Issuer has made a response or any third party
acquires 15% or more of the outstanding Issuer Common Stock
prior to the Company Shareholders Meeting, and either (A) the
requisite vote of the shareholders of Issuer to approve the
Merger is not obtained or (B) the Merger Agreement is
terminated pursuant to Section 7.1(g) of the Merger Agreement
where the Issuer's breach is willful and intentional or is
terminated pursuant to Section 7.1(d) of the Merger Agreement,
and in the case of either (A) or (B) above, within 12 months
after termination of the Merger Agreement the Issuer enters
into an agreement providing for an Alternative Proposal.
(b) In the event Grantee wishes to exercise the Option at
such time as the Option is exercisable, Grantee shall deliver written
notice (the "Exercise Notice") to Issuer specifying its intention to
exercise the Option, the total number of Option Shares it wishes to
purchase, and a date and time for the closing of such purchase (a
"Closing") not less than three nor more than 30 business days after the
later of (i) the date such Exercise Notice is given and (ii) the
expiration or termination of any applicable waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the
"HSR Act"). If prior to the Expiration Date (as defined in Section 11
below) any person or group (other than Grantee or its affiliates) shall
have made a bona fide proposal that becomes publicly disclosed, with
respect to a tender offer or exchange offer for 50% or more of the then
outstanding shares of Issuer Common Stock (a "Share Proposal"), a
merger, consolidation, or other business combination (a "Merger
Proposal"), or any acquisition of a material portion of the assets of
Issuer (an "Asset Proposal"), or shall have acquired 50% or more of the
then outstanding shares of Issuer Common Stock (a "Share Acquisition")
, and this Option is then exercisable, then Grantee, in lieu of
exercising the Option, shall have the right at any time on or after the
date the Termination Fee (defined below) under the Merger Agreement
becomes due and payable to request in writing that Issuer pay, and
promptly (but in any event not more than five business days) after
Grantee makes such request, Issuer shall, subject to Section 2(c)
below, pay to Grantee by certified check, official bank check or wire
transfer pursuant to Grantee's instructions, in cancellation of the
option, an amount in cash (the "Cancellation Amount") equal to (i) the
lesser of
(x) the excess over the Option Price of the greater
of (A) the last sale price of a share of Issuer Common Stock
as reported on the Nasdaq National Market on the last trading
day prior to the date of the Exercise Notice, or (B)(1) the
highest price per share of Issuer Common Stock offered to be
paid or paid by any such person or group pursuant to or in
connection with a Share Proposal, a Share Acquisition, or a
Merger Proposal, or (2) the aggregate consideration offered to
be paid or paid in any transaction or proposed transaction in
connection with an Asset Proposal, divided by the number of
shares of Issuer Common Stock then outstanding, and
(y)$1.718 [$2.75 million divided by initial number of
Option Shares],
multiplied by (ii) the number of Option Shares then covered by the
Option; provided, however, that if, prior to payment of the
Cancellation Amount, Grantee has been paid by Issuer the termination
fee described in Section 7.2 of the Merger Agreement (the "Termination
Fee"), then the Cancellation Amount shall be reduced (but not below
zero) to the extent necessary so that the sum of the Termination Fee
and the Cancellation Amount shall not exceed $3.6 million. If all or a
portion of the price per share of Issuer Common Stock offered, paid, or
payable or the aggregate consideration offered, paid, or payable for
the assets of Issuer, each as contemplated by the preceding sentence,
consists of noncash consideration, such price or aggregate
consideration shall be the cash consideration, if any, plus the fair
market value of the noncash consideration as mutually determined by the
investment bankers of Issuer and the investment bankers of Grantee.
(c) Following exercise of the Option by Grantee, in the event
that Grantee sells, pledges, or otherwise disposes of (including,
without limitation, by merger or exchange) any of the Option Shares (a
"Sale"), then any Termination Fee due and payable by Issuer following
such time shall be reduced to the extent necessary so that the sum of
(x) the Termination Fee and
(y) the amount received (whether in cash, loan
proceeds, securities, or otherwise) by Grantee in such Sale
less the exercise price of such Option Shares sold in the Sale
(the "Option Share Profit")
shall not exceed $3.6 million. If Issuer has paid to Grantee the
Termination Fee prior to the Sale, then Grantee shall immediately remit
to Issuer by wire transfer of immediately available funds to a bank
account designated by Issuer the excess, if any, of the Option Share
Profit over $850,000.
3. Payment of Option Price and Delivery of Certificate. Any Closings
under Section 2 of this Agreement shall be held at the principal executive
offices of Issuer, or at such other place as Issuer and Grantee may agree. At
any Closing hereunder, (a) Grantee or its designee will make payment to Issuer
of the aggregate price for the Option Shares being so purchased by delivery of a
certified check, official bank check, or wire transfer of funds pursuant to
Issuer's instructions payable to Issuer in an amount equal to the product
obtained by multiplying the Option Price by the number of Option Shares to be
purchased, and (b) upon receipt of such payment Issuer will deliver to Grantee
or its designee (which shall be a wholly-owned subsidiary of Grantee) a
certificate or certificates representing the number of validly issued, fully
paid, and nonassessable Option Shares so purchased, in the denominations and
registered in such names (which shall be Grantee or a wholly-owned subsidiary of
Grantee) designated in writing to Issuer by Grantee.
4. Registration and Listing of Option Shares.
(a) Issuer agrees to use its reasonable best efforts to (i)
effect as promptly as possible upon the request of Grantee and (ii)
cause to become and remain effective for a period of not less than six
months (or such shorter period as may be necessary to effect the
distribution of such shares) the registration under the 1933 Act, and
any applicable state securities laws, of all or any part of the Option
Shares as may be specified in such request; provided, however, that (i)
Grantee shall have the right to select the managing underwriter for any
such offering after consultation with Issuer, which managing
underwriter shall be reasonably acceptable to Issuer, and (ii) Grantee
shall not be entitled to more than two effective registration
statements hereunder.
(b) In addition to such demand registrations, if Issuer
proposes to effect a registration of Issuer Common Stock for its own
account or for the account of any other shareholder of Issuer (other
than on Form S-4 or Form S-8), Issuer will give prompt written notice
to all holders of Options or Option Shares of its intention to do so
and shall use its reasonable best efforts to include therein all Option
Shares requested by Grantee to be so included, provided, however, if
Issuer is in registration with respect to an underwritten public
offering of shares of Issuer Common Stock, and if in the good faith
judgment of the managing underwriter or managing underwriters, or, if
none, the sole underwriter, of such offering the inclusion of the
Option Shares and any other selling shareholder's shares would
interfere with the successful marketing of the shares of Issuer Common
Stock, the number of Option Shares and shares of other selling
shareholders otherwise to be covered in the registration statement
contemplated hereby may be reduced prorata. No registration effected
under this Section 4(b) shall relieve Issuer of its obligations to
effect demand registrations under Section 4(a) hereof.
(c) Registrations effected under this Section 4 shall be
effected at Issuer's expense, including the reasonable fees and
expenses of counsel to the holder of Options or Option Shares, but
excluding underwriting discounts and commissions to brokers or dealers.
In connection with each registration under this Section 4, Issuer shall
indemnify and hold each holder of Options or Option Shares
participating in such offering (a "Holder"), its underwriters, and each
of their respective affiliates harmless against any and all losses,
claims, damage, liabilities, and expenses (including, without
limitation, investigation expenses and fees and disbursements of
counsel and accountants), joint or several, to which such Holder, its
underwriters, and each of their respective affiliates may become
subject, under the 1933 Act or otherwise, insofar as such losses,
claims, damages, liabilities, or expenses (or actions in respect
thereof) arise out of or are based upon an untrue statement or alleged
untrue statement of a material fact contained in any registration
statement (including any prospectus therein), or any amendment or
supplement thereto, or arise out of or are based upon the omission or
alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading,
other than such losses, claims, damages, liabilities, or expenses (or
actions in respect thereof) that arise out of or are based upon an
untrue statement or alleged untrue statement of a material fact
contained in written information furnished by a Holder to Issuer
expressly for use in such registration statement.
(d) In connection with any registration statement pursuant to
this Section 4, each Holder agrees to furnish Issuer with such
information concerning itself and the proposed sale or distribution as
shall reasonably be required in order to ensure compliance with the
requirements of the 1933 Act. In addition, Grantee shall indemnify and
hold Issuer, its underwriters and each of their respective affiliates
harmless against any and all losses, claims, damages, liabilities, and
expenses (including, without limitation, investigation expenses and
fees and disbursements of counsel and accountants), joint or several,
to which Issuer, its underwriters, and each of their respective
affiliates may become subject under the 1933 Act or otherwise, insofar
as such losses, claims, damages, liabilities, or expenses (or actions
in respect thereof) arise out of or are based upon an untrue statement
or alleged untrue statement of a material fact contained in written
information furnished by any Holder to Issuer expressly for use in such
registration statement.
(e) Upon the issuance of Option Shares hereunder, Issuer will
use its reasonable best efforts promptly to list such Option Shares
with the Nasdaq National Market or on such national or other exchange
on which the shares of Issuer Common Stock are at the time listed.
5. Representations and Warranties of Issuer. Issuer hereby represents
and warrants to Grantee as follows:
(a) Issuer is a corporation duly organized, validly existing,
and in good standing under the laws of the State of Minnesota and has
requisite power and authority to enter into and perform this Agreement.
(b) The execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby have been duly and
validly authorized by the Board of Directors of Issuer, and no other
corporate proceedings on the part of Issuer are necessary to authorize
this Agreement or to consummate the transactions contemplated hereby.
The Board of Directors of Issuer has duly approved the issuance and
sale of the Option Shares, upon the terms and subject to the conditions
contained in this Agreement, and the consummation of the transactions
contemplated hereby. This Agreement has been duly and validly executed
and delivered by Issuer and, assuming this Agreement has been duly and
validly authorized, executed, and delivered by Grantee, constitutes a
valid and binding obligation of Issuer enforceable against Issuer in
accordance with its terms, subject to bankruptcy, insolvency,
reorganization, moratorium, or other similar laws affecting or relating
to creditors, rights generally; the availability of injunctive relief
and other equitable remedies; and limitations imposed by law on
indemnification for liability under federal securities laws.
(c) Issuer has taken all necessary action to authorize and
reserve for issuance and to permit it to issue, and at all times from
the date of this Agreement through the date of expiration of the Option
will have reserved for issuance upon exercise of the Option, such
number of authorized shares of Issuer Common Stock as is equal to the
number of Option Shares (or such other amount as may be required
pursuant to Section 10 hereof), each of which, upon issuance pursuant
to this Agreement and when paid for as provided herein, will be validly
issued, fully paid, and nonassessable, and shall be delivered free and
clear of all claims, liens, charges, encumbrances, and security
interests and not subject to any preemptive rights.
(d) The execution, delivery, and performance of this Agreement
by Issuer and the consummation by it of the transactions contemplated
hereby except as required by the HSR Act (if applicable), and, with
respect to Section 4, compliance with the provisions of the 1933 Act
and any applicable state securities laws, do not require the consent,
waiver, approval, license, or authorization of or result in the
acceleration of any obligation under, or constitute a default under,
any term, condition, or provision of any charter or bylaw, or any
indenture, mortgage, lien, lease, agreement, contract, instrument,
order, judgment, ordinance, regulation, or decree or any restriction to
which Issuer or any property of Issuer or its subsidiaries is bound,
except where the failure to obtain such consents, waivers, approvals,
licenses, or authorizations or where such acceleration or defaults
could not, individually or in the aggregate, reasonably be expected to
have a Company Material Adverse Effect.
6. Representations and Warranties of Grantee. Grantee hereby represents
and warrants to Issuer that:
(a) Grantee is a corporation duly organized, validly existing,
and in good standing under the laws of the State of Minnesota and has
requisite power and authority to enter into and perform this Agreement.
(b) The execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby have been duly and
validly authorized by the Board of Directors of Grantee, and no other
corporate proceedings on the part of Grantee are necessary to authorize
this Agreement or to consummate the transactions contemplated hereby.
This Agreement has been duly and validly executed and delivered by
Grantee and, assuming this Agreement has been duly executed and
delivered by Issuer, constitutes a valid and binding obligation of
Grantee enforceable against Grantee in accordance with its terms,
subject to bankruptcy, insolvency, reorganization, moratorium, or other
similar laws affecting or relating to creditors' rights generally; the
availability of injunctive relief and other equitable remedies; and
limitations imposed by law on indemnification for liability under
federal securities laws.
(c) Grantee or its designee is acquiring the Option and it
will acquire the Option Shares issuable upon the exercise thereof for
its own account and not with a view to the distribution or resale
thereof in any manner not in accordance with applicable law.
7. Covenants of Grantee. Grantee agrees not to transfer or otherwise
dispose of the Option or the Option Shares, or any interest therein, except in
compliance with the 1933 Act and any applicable state securities law. Grantee
further agrees to the placement of the following legend on the certificates)
representing the Option Shares (in addition to any legend required under
applicable state securities laws):
"THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER EITHER (1) THE SECURITIES ACT OF 1933, AS
AMENDED (THE "ACT"), OR (2) ANY APPLICABLE STATE LAW GOVERNING
THE OFFER AND SALE OF SECURITIES. NO TRANSFER OR OTHER
DISPOSITION OF THESE SHARES, OR OF ANY INTEREST THEREIN, MAY
BE MADE EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE ACT AND SUCH OTHER STATE LAWS OR PURSUANT TO
EXEMPTIONS FROM REGISTRATION UNDER THE ACT, SUCH OTHER STATE
LAWS, AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER."
8. Reasonable Best Efforts. Grantee and Issuer shall take, or cause to
be taken, all reasonable action to consummate and make effective the
transactions contemplated by this Agreement, including, without limitation,
reasonable best efforts to obtain any necessary consents of third parties and
governmental agencies and the filing by Grantee and Issuer promptly after the
date hereof of any required HSR Act notification forms and the documents
required to comply with the HSR Act.
9. Certain Conditions. The obligation of Issuer to issue Option Shares
under this Agreement upon exercise of the Option shall be subject to the
satisfaction or waiver of the following conditions:
(a) any waiting periods applicable to the acquisition of the
Option Shares by Grantee pursuant to this Agreement under the HSR Act
shall have expired or been terminated;
(b) the representations and warranties of Grantee made in
Section 6 of this Agreement shall be true and correct in all material
respects as of the date of the Closing for the issuance of such Option
Shares; and
(c) no order, decree, or injunction entered by any court of
competent jurisdiction or governmental, regulatory, or administrative
agency or commission in the United States shall be in effect that
prohibits the exercise of the option or acquisition of Option Shares
pursuant to this Agreement.
10. Adjustments Upon Changes in Capitalization. In the event of any
change in the number of issued and outstanding shares of Issuer Common Stock by
reason of any stock dividend, stock split, recapitalization, merger, rights
offering, share exchange, or other change in the corporate or capital structure
of Issuer, Grantee shall receive, upon exercise of the Option, the stock or
other securities, cash, or property to which Grantee would have been entitled if
Grantee had exercised the Option and had been a holder of record of shares of
Issuer Common Stock on the record date fixed for determination of holders of
shares of Issuer Common Stock entitled to receive such stock or other
securities, cash, or property at the same aggregate price as the aggregate
Option Price of the Option Shares.
11. Expiration. The Option shall expire at the earlier of (a) the
Effective Time (as defined in the Merger Agreement) or (b) if exercisable
pursuant to Section 2 hereof, 18 months after termination of the Merger
Agreement in accordance with the terms thereof (such expiration date is referred
to as the "Expiration Date").
12. General Provisions.
(a) Survival. All of the representations, warranties, and
covenants contained herein shall survive each Closing and shall be
deemed to have been made as of the date hereof and as of the date of
each Closing.
(b) Further Assurances. If Grantee exercises the Option, or
any portion thereof, in accordance with the terms of this Agreement,
Issuer and Grantee will execute and deliver all such further documents
and instruments and use their reasonable best efforts to take all such
further action as may be necessary in order to consummate the
transactions contemplated thereby.
(c) Severability. It is the desire and intent of the parties
that the provisions of this Agreement be enforced to the fullest extent
permissible under the law and public policies applied in each
jurisdiction in which enforcement is sought. Accordingly, in the event
that any provision of this Agreement would be held in any jurisdiction
to be invalid, prohibited, or unenforceable for any reason, such
provision, as to such jurisdiction, shall be ineffective, without
invalidating the remaining provisions of this Agreement or affecting
the validity or enforceability of such provision in any other
jurisdiction. Notwithstanding the foregoing, if such provision could be
more narrowly drawn so as not be invalid, prohibited, or unenforceable
in such jurisdiction, it shall, as to such jurisdiction, be so narrowly
drawn, without invalidating the remaining provisions of this Agreement
or affecting the validity or enforceability of such provision in any
other jurisdiction.
(d) Assignment. This Agreement shall be binding on and inure
to the benefit of the parties hereto and their respective successors
and assigns; provided, however, that Issuer shall not be entitled to
assign or otherwise transfer any of its rights or obligations hereunder
and, prior to the option becoming exercisable pursuant to Section 2,
this Agreement may not be assigned by Grantee.
(e) Specific Performance. The parties agree and acknowledge
that in the event of a breach of any provision of this Agreement, the
aggrieved party would be without an adequate remedy at law. The parties
therefore agree that in the event of a breach of any provision of this
Agreement, the aggrieved party may elect to institute and prosecute
proceedings in any court of competent jurisdiction to enforce specific
performance or to enjoin the continuing breach of such provision, as
well as to obtain damages for breach of this Agreement. By seeking or
obtaining any such relief, the aggrieved party will not be precluded
from seeking or obtaining any other relief to which it may be entitled.
(f) Amendments. This Agreement may not be modified, amended,
altered, or supplemented except upon the execution and delivery of a
written agreement executed by Grantee and Issuer.
(g) Notices. All notices, requests, claims, demands, and other
communications hereunder shall be in writing and shall be deemed to be
sufficient if contained in a written instrument and shall be deemed
given if delivered personally, telecopied, sent by
nationally-recognized overnight courier or mailed by registered or
certified mail (return receipt requested), postage prepaid, to the
other party at the following addresses (or such other address for a
party as shall be specified by like notice):
If to Grantee:
Medtronic, Inc.
7000 Central Avenue N.E.
Minneapolis, MN 55432
with separate copies thereof addressed to
Attention: General Counsel
FAX: (612) 572-5459
and
Attention: Vice President and Chief Development Officer
FAX: (612) 572-5404
If to Issuer:
AVECOR Cardiovascular, Inc.
7611 Northland Drive
Minneapolis, MN 55428
FAX: (612) 391-9106
Attention: Anthony Badolato, CEO
with a copy to:
Oppenheimer Wolff & Donnelly LLP
Plaza VII Building
45 South Seventh Street
Minneapolis, MN 55402
FAX: (612) 7100
Attention: Richard Lareau
(h) Headings. The headings contained in this Agreement are
for reference purposes only and shall not affect in any way the meaning
or interpretation of this Agreement.
(i) Counterparts. This Agreement may be executed in one or
more counterparts, each of which shall be an original, but all of which
together shall constitute one and the same agreement.
(j) Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of Minnesota
applicable to contracts made and to be performed therein.
(k) Jurisdiction and Venue. Each of Issuer and Grantee hereby
agrees that any proceeding relating to this Agreement shall be brought
in a state court of Minnesota. Each of Issuer and Grantee hereby
consents to personal jurisdiction in any such action brought in any
such Minnesota court, consents to service of process by registered mail
made upon such party and such party's agent, and waives any objection
to venue in any such Minnesota court or to any claim that any such
Minnesota court is an inconvenient forum.
(l) Entire Agreement. This Agreement, the Confidentiality
Agreement, and the Merger Agreement and any documents and instruments
referred to herein and therein constitute the entire agreement between
the parties hereto and thereto with respect to the subject matter
hereof and thereof and supersede all other prior agreements and
understandings, both written and oral, between the parties with respect
to the subject matter hereof and thereof. This Agreement shall be
binding upon, inure to the benefit of, and be enforceable by the
successors and permitted assigns of the parties hereto. Nothing in this
Agreement shall be construed to give any person other than the parties
to this Agreement or their respective successors or permitted assigns
any legal or equitable right, remedy, or claim under or in respect of
this Agreement or any provision contained herein.
(m) Expenses. Except as otherwise provided in this Agreement
or the Merger Agreement, each party shall pay its own expenses incurred
in connection with this Agreement.
<PAGE>
IN WITNESS WHEREOF, the parties have caused this Agreement to be signed
by their respective officers thereunto duly authorized as of the date first
written above.
MEDTRONIC, INC.
By /s/ Michael D. Ellwein
Its: Vice President
AVECOR CARDIOVASCULAR, INC.
By /s/ Anthony Badolato
Its: CEO
Exhibit C
AGREEMENT TO FACILITATE MERGER
DATE: July 12, 1998
PARTIES:
Medtronic, Inc., (hereinafter "Parent")
a Minnesota corporation
and
------------------------,
an individual officer and/or director
of AVECOR Cardiovascular, Inc. (hereinafter "Shareholder")
RECITALS:
A. Shareholder is the legal or beneficial owner of shares of Common
Stock of AVECOR Cardiovascular, Inc., a Minnesota corporation (the "Company"),
and the holder of options, warrants, or other rights to acquire shares of
Company Common Stock.
B. Parent, the Company, and a wholly-owned subsidiary of Parent are
entering into an Agreement and Plan of Merger (the "Merger Agreement") pursuant
to which it is proposed that Parent's subsidiary will merge with and into the
Company (the "Merger") and as a result of which the outstanding shares of
Company Common Stock shall be converted into Parent Common Stock.
C. Shareholder deems it to be in Shareholder's best interest and in the
best interests of the Company and all other shareholders of the Company that the
Merger Agreement be approved, ratified, and confirmed by the shareholders of the
Company, and it is a condition to Parent's obligations under the Merger
Agreement that Shareholder enter into this Agreement.
D. It is understood and acknowledged by Shareholder that Parent's
execution of the Merger Agreement is being done in reliance upon the prior
execution and delivery of this Agreement, that Shareholder is entering into this
Agreement prior to the Company's execution and delivery of the Stock Option
Agreement referred to in the Merger Agreement, that Parent will incur
substantial expenses proceeding toward consummation of the Merger as
contemplated by the Merger Agreement, and that such expenses will be undertaken
in reliance upon and as a result of the agreements and undertakings of
Shareholder set forth herein.
<PAGE>
NOW, THEREFORE, in consideration of the foregoing, and in order to
induce Parent to execute the Merger Agreement and to proceed as contemplated by
the Merger Agreement toward the consummation of the Merger, and for other good
and valuable consideration, the receipt and adequacy of which is hereby
acknowledged, the parties hereto agree as follows:
AGREEMENTS:
1. Vote in Favor of Merger. Shareholder, in his or her capacity as a
shareholder of the Company or as a representative with the authority to vote
shares of Company Common Stock, agrees to vote (or caused to be voted) all
shares of Company Common Stock with respect to which Shareholder presently owns
or controls voting power, and all shares of Company Common Stock with respect to
which Shareholder in the future acquires ownership or voting power, at any
meeting of the shareholders of the Company, and in any action by written consent
of the shareholders of the Company, (i) in favor of the approval, consent, and
ratification of the Merger Agreement and the Merger, and (ii) against any action
that would impede, interfere, or discourage the Merger, would facilitate an
acquisition of the Company, in any manner, by a party (other than Parent), or
would result in any breach of representation, warranty, covenant, or agreement
of the Company under the Merger Agreement. To the extent inconsistent with the
foregoing provisions of this Section 1, Shareholder hereby revokes any and all
previous proxies with respect to any shares of Company Common Stock that
Shareholder owns or has the right to vote. Nothing in this Agreement shall be
deemed to restrict or limit Shareholder's right to act in his or her capacity as
an officer or director of the Company consistent with his or her fiduciary
obligations in such capacity.
2. Representations and Warranties of Shareholder. Shareholder
represents and warrants to Parent that Shareholder has the legal capacity to
enter into and perform all of Shareholder's obligations under this Agreement.
The execution, delivery, and performance of this Agreement by Shareholder will
not violate any other agreement to which Shareholder is a party, including,
without limitation, any voting agreement, shareholders agreement, or voting
trust. This Agreement has been duly executed and delivered by Shareholder and
constitutes a legal, valid, and binding agreement of Shareholder, enforceable in
accordance with its terms, except as the enforcement thereof may be limited by
bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium, and
similar laws, now or hereafter in effect.
3. Successors and Assigns. This Agreement shall be binding upon any
permitted purchasers, donees, pledgees, and other transferees of Company Common
stock legally or beneficially owned by Shareholder. Shareholder agrees not to
make any sales, gifts, transfers, pledges, or other dispositions of Company
Common Stock without first making any such transferee or pledgee fully aware of
the obligations under this Agreement and obtaining such transferee's or
pledgee's written agreement to comply with the terms hereof.
4. Injunctive Relief. Shareholder agrees that in the event of
Shareholder's breach of any provision of this Agreement, Parent may be without
an adequate remedy at law. Shareholder therefore agrees that in the event of
Shareholder's breach of any provision of this Agreement, Parent may elect to
institute and prosecute proceedings in any court of competent jurisdiction to
enforce specific performance or to enjoin the continuing breach of such
provision, as well as to obtain damages for breach of this Agreement. By seeking
or obtaining any such relief, Parent will not be precluded from seeking or
obtaining any other relief to which it may be entitled.
5. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original and all of which
together shall constitute one and the same document.
6. Further Assurances. Shareholder shall execute and deliver such
additional documents and take such further action as may be necessary or
desirable to consummate the transactions contemplated by this Agreement.
7. Third-Party Beneficiaries. Nothing in this Agreement, expressed or
implied, shall be construed to give any person other than the parties hereto any
legal or equitable right, remedy, or claim under or by reason of this Agreement
or any provision contained herein.
8. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Minnesota (regardless of the laws that
might otherwise govern under applicable Minnesota principles of conflicts of
laws).
9. Effectiveness. If this Agreement is executed by Shareholder prior to
the approval of the Merger Agreement by the Company's Board of Directors, then
this Agreement shall be subject to, and shall become effective only upon, the
approval of the Merger Agreement by the Company's Board of Directors. This
Agreement shall terminate upon termination of the Merger Agreement in accordance
with its terms.
<PAGE>
IN WITNESS WHEREOF, Parent has caused this Agreement to Facilitate
Merger to be executed by its duly authorized officer, and Shareholder has
executed this Agreement, as of the date and year first above written.
MEDTRONIC, INC.
By_________________________________
Its: Vice President
SHAREHOLDER:
___________________________________
[signature]
___________________________________
[print name]
AGREEMENT AND PLAN OF MERGER
BY AND AMONG
MEDTRONIC, INC.,
AC MERGER CORP.,
AND
AVECOR CARDIOVASCULAR, INC.
July 12, 1998
<PAGE>
iii
TABLE OF CONTENTS
ARTICLE 1 THE MERGER; CONVERSION OF SHARES....................................1
1.1 The Merger.......................................................1
1.2 Effective Time...................................................2
1.3 Conversion of Shares.............................................2
1.4 Dissenting Shares................................................3
1.5 Exchange of Company Common Stock.................................4
1.6 Exchange of Merger Subsidiary Common Stock.......................6
1.7 Stock Options....................................................6
1.8 Capitalization Changes...........................................7
1.9 Articles of Incorporation of the Surviving Corporation...........8
1.10 Bylaws of the Surviving Corporation.............................8
1.11 Directors and Officers of the Surviving Corporation.............8
ARTICLE 2 CLOSING.............................................................8
2.1 Time and Place...................................................8
2.2 Filings at the Closing...........................................8
ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF THE COMPANY.......................9
3.1 Disclosure Schedule..............................................9
3.2 Organization.....................................................9
3.3 Authorization...................................................10
3.4 Capitalization..................................................10
3.5 Reports and Financial Statements................................11
3.6 Absence of Undisclosed Liabilities..............................12
3.7 Consents and Approvals..........................................12
3.8 Compliance with Laws............................................13
3.9 Litigation......................................................13
3.10 Absence of Material Adverse Changes............................14
3.11 Environmental Laws and Regulations.............................14
3.12 Officers, Directors and Employees..............................16
3.13 Taxes..........................................................16
3.14 Contracts......................................................17
3.15 Title to Properties; Liens.....................................18
3.16 Permits, Licenses, Etc.........................................18
3.17 Intellectual Property Rights...................................19
3.18 Benefit Plans..................................................20
3.19 Minute Books...................................................22
3.20 Insurance Policies.............................................22
3.21 Bank Accounts..................................................22
3.22 Powers of Attorney.............................................22
3.23 Product Liability Claims.......................................22
3.24 Warranties.....................................................22
3.25 Inventories....................................................23
3.26 Relations with Suppliers and Customers.........................23
3.27 No Finders.....................................................23
3.28 Proxy Statement................................................24
3.29 Merger Filings.................................................24
3.30 Fairness Opinion...............................................24
3.31 State Takeover Laws............................................24
ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUBSIDIARY.....25
4.1 Organization....................................................25
4.2 Authorization...................................................25
4.3 Capitalization..................................................26
4.4 Consents and Approvals..........................................26
4.5 Reports; Financial Statements; Absence of Changes...............27
4.6 Registration Statement..........................................28
4.7 Merger Filings..................................................28
4.8 No Finders......................................................28
ARTICLE 5 COVENANTS..........................................................28
5.1 Conduct of Business of the Company..............................28
5.2 No Solicitation.................................................32
5.3 Access and Information..........................................32
5.4 Approval of Shareholders; Proxy Statement; Registration
Statement.......................................................33
5.5 Consents........................................................34
5.6 Affiliates' Letters.............................................34
5.7 Expenses........................................................35
5.8 Further Actions.................................................35
5.9 Regulatory Approvals............................................35
5.10 Certain Notifications..........................................36
5.11 Voting of Shares...............................................36
5.12 Noncompetition Agreements......................................36
5.13 NYSE Listing Application.......................................37
5.14 Indemnification................................................37
5.15
5.16 Subsidiary Shares..............................................37
5.17 Stock Option Agreement.........................................37
5.18 Benefit Plans and Employee Matters.............................38
5.19 Tax 38
ARTICLE 6 CLOSING CONDITIONS.................................................38
6.1 Conditions to Obligations of Parent, Merger Subsidiary,
and the Company.................................................38
6.2 Conditions to Obligations of Parent and Merger Subsidiary.......39
6.3 Conditions to Obligations of the Company........................40
ARTICLE 7 TERMINATION AND ABANDONMENT........................................41
7.1 Termination.....................................................41
7.2 Effect of Termination...........................................42
ARTICLE 8 MISCELLANEOUS......................................................44
8.1 Amendment and Modification......................................44
8.2 Waiver of Compliance; Consents..................................44
8.3 Investigation; Survival of Representations and Warranties.......44
8.4 Notices.........................................................45
8.5 Assignment......................................................45
8.6 Governing Law...................................................46
8.7 Counterparts....................................................46
8.8 Knowledge.......................................................46
8.9 Interpretation..................................................46
8.10 Publicity......................................................46
8.11 Entire Agreement...............................................46
EXHIBITS:
Exhibit A: Form of Plan of Merger
Exhibit B: Form of Affiliate's Letter
Exhibit C: Form of Agreement to Facilitate Merger
Exhibit D: Form of Noncompetition Agreement
Exhibit E: Form of Stock Option Agreement
Exhibit F: Form of Opinion of the Company's Counsel
Exhibit G: Form of Opinion of Parent's Counsel
<PAGE>
AGREEMENT AND PLAN OF MERGER
THIS AGREEMENT is dated as of July 12, 1998, by and among Medtronic,
Inc., a Minnesota corporation ("Parent"), AC Merger Corp., a Minnesota
corporation and wholly-owned subsidiary of Parent ("Merger Subsidiary"), and
AVECOR Cardiovascular, Inc., a Minnesota corporation (the "Company").
WHEREAS, the Boards of Directors of Parent, Merger Subsidiary, and the
Company have approved the merger of Merger Subsidiary with and into the Company
(the "Merger") upon the terms and subject to the conditions set forth herein;
and
WHEREAS, for federal income tax purposes, it is intended that the
Merger shall qualify as a reorganization within the meaning of Section
368(a)(1)(A) and (a)(2)(E) of the Internal Revenue Code of 1986, as amended (the
"Code"); and
WHEREAS, prior to the execution of the Stock Option Agreement described
in Section 5.17, officers and directors of the Company have, to induce Parent to
execute this Agreement, executed and delivered to Parent the Agreements to
Facilitate Merger described in Section 5.11; and
WHEREAS, as a further and subsequent inducement to have Parent execute
this Agreement, Parent and the Company are entering into the Stock Option
Agreement described in Section 5.17 hereof after execution and delivery of the
Agreements to Facilitate Merger described in Section 5.11; and
WHEREAS, the parties hereto desire to make certain representations,
warranties, and agreements in connection with the Merger and also to prescribe
various conditions to the Merger;
NOW, THEREFORE, in consideration of the foregoing premises and the
mutual representations, warranties, covenants, and agreements contained herein,
the parties hereto agree as follows:
ARTICLE 1
THE MERGER; CONVERSION OF SHARES
1.1 The Merger. Subject to the terms and conditions of this
Agreement, at the Effective Time (as defined in Section 1.2 hereof), Merger
Subsidiary shall be merged with and into the Company in accordance with the
provisions of the Minnesota Business Corporation Act (the "MBCA"), whereupon the
separate corporate existence of Merger Subsidiary shall cease, and the Company
shall continue as the surviving corporation (the "Surviving Corporation"). From
and after the Effective Time, the Surviving Corporation shall possess all the
rights, privileges, powers, and franchises and be subject to all the
restrictions, disabilities, and duties of the Company and Merger Subsidiary, all
as more fully described in the MBCA.
1.2 Effective Time. As soon as practicable after each of the
conditions set forth in Article 6 has been satisfied or waived, the Company and
Merger Subsidiary will file, or cause to be filed, with the Secretary of State
of the State of Minnesota Articles of Merger for the Merger, which Articles
shall be in the form required by and executed in accordance with the applicable
provisions of the MBCA and shall include as a part thereof a plan of merger (the
"Plan of Merger") substantially in the form attached hereto as Exhibit A. The
Merger shall become effective at the time such filing is made or, if agreed to
by Parent and the Company, such later time or date set forth in the Articles of
Merger (the "Effective Time").
1.3 Conversion of Shares. At the Effective Time, by virtue of the
Merger and without any action on the part of any holder of any share of capital
stock of the Company or Merger Subsidiary:
(a) Each share of common stock of the Company, par value $.01
per share ("Company Common Stock"), issued and outstanding immediately
prior thereto (except for Dissenting Shares, as defined in Section 1.4
hereof, and except for shares referred to in Section 1.3(b) hereof)
shall be converted into the right to receive the fraction of a share
(subject to adjustment as provided below, the "Conversion Fraction") of
common stock of Parent, par value $.10 per share ("Parent Common
Stock"), equal to $11.125 divided by the Parent Average Stock Price.
The "Parent Average Stock Price" shall mean the average (rounded to the
nearest full cent, with the cents rounded up if the third decimal place
is 5 or more) of the daily closing sale prices of a share of Parent
Common Stock as reported on the New York Stock Exchange ("NYSE")
Composite Tape, as reported in The Wall Street Journal, for the 18
consecutive NYSE trading days ending on and including the second NYSE
trading day immediately preceding the Effective Time.
Notwithstanding the foregoing, if the sum of the number of
shares of Company Common Stock outstanding immediately prior to the
Effective Time plus the number of shares subject to then outstanding
options, warrants, or other rights to acquire shares of Company Common
Stock (collectively, "Company Stock Acquisition Rights") is greater
than 8,879,725 shares plus that number of shares issuable pursuant to
the current offering period in process as of the date of this Agreement
under the Company's Employee Stock Purchase Plan or if the aggregate
exercise price of all such Company Stock Acquisition Rights then
outstanding is less than the aggregate exercise price reflected in
Section 3.4 hereof, then the $11.125 amount per share of Company Common
Stock, as described above, shall be reduced to an amount, if lower,
equal to (i) $11.125 times [8,879,725 shares plus that number of shares
issuable pursuant to the current offering period in process as of the
date of this Agreement under the Company's Employee Stock Purchase
Plan] minus the aggregate exercise price reflected in Section 3.4
hereof plus the aggregate amount received by the Company as a result of
any issuance of Company Common Stock after the date of this Agreement
and prior to the Effective Time plus the aggregate exercise price of
all Company Stock Acquisition Rights outstanding immediately prior to
the Effective Time divided by (ii) the sum of (A) the number of shares
of Company Common Stock outstanding immediately prior to the Effective
Time plus (B) the number of shares subject to Company Stock Acquisition
Rights then outstanding.
An appropriate adjustment shall similarly be made in the event
that, prior to the Effective Time, the outstanding shares of Company
Common Stock, without new consideration, are changed into or exchanged
for a different kind of shares or securities through a reorganization,
reclassification, stock dividend, stock combination, or other like
change in the Company's capitalization. Notwithstanding the foregoing,
nothing in this section shall be deemed to constitute authorization or
permission for or consent from Parent or Merger Subsidiary to any
increase in the number of shares of Company Common Stock outstanding or
subject to outstanding Company Stock Acquisition Rights, to any
decrease in the exercise price of such Rights, or to any
reorganization, reclassification, stock dividend, stock combination, or
other like change in capitalization.
(b) Each share of Company Common Stock issued and outstanding
immediately prior to the Effective Time that is then owned beneficially
or of record by Parent, Merger Subsidiary, or any direct or indirect
subsidiary of Parent or the Company shall be cancelled without payment
of any consideration therefor and without any conversion thereof.
(c) Each share of any other class of capital stock of the
Company (other than Company Common Stock) shall be cancelled without
payment of any consideration therefor and without any conversion
thereof.
(d) Each share of common stock of Merger Subsidiary, par value
$.01 per share ("Merger Subsidiary Common Stock"), issued and
outstanding immediately prior to the Effective Time shall be converted
into one share of the common stock of the Surviving Corporation, par
value $.01 per share ("Surviving Corporation Common Stock").
1.4 Dissenting Shares. Notwithstanding any provision of this Agreement to
the contrary, each outstanding share of Company Common Stock, the holder of
which has demanded and perfected such holder's right to dissent from the Merger
and to be paid the fair value of such shares in accordance with Sections
302A.471 and 302A.473 of the MBCA and, as of the Effective Time, has not
effectively withdrawn or lost such dissenters' rights ("Dissenting Shares"),
shall not be converted into or represent a right to receive the Parent Common
Stock into which shares of Company Common Stock are converted pursuant to
Section 1.3 hereof, but the holder thereof shall be entitled only to such rights
as are granted by the MBCA. Parent shall cause the Company to make all payments
to holders of shares of Company Common Stock with respect to such demands in
accordance with the MBCA. The Company shall give Parent (i) prompt written
notice of any notice of intent to demand fair value for any shares of Company
Common Stock, withdrawals of such notices, and any other instruments served
pursuant to the MBCA and received by the Company, and (ii) the opportunity to
conduct jointly all negotiations and proceedings with respect to demands for
fair value for shares of Company Common Stock under the MBCA. The Company shall
not, except with the prior written consent of Parent or as otherwise required by
law, voluntarily make any payment with respect to any demands for fair value for
shares of Company Common Stock or offer to settle or settle any such demands.
1.5 Exchange of Company Common Stock.
(a) Promptly after the Effective Time, Parent shall cause
Parent's stock transfer agent or such other person as Parent may
appoint to act as exchange agent (the "Exchange Agent") to mail to each
holder of record (other than Parent, Merger Subsidiary, or any other
subsidiary of Parent or the Company) of a certificate or certificates
that immediately prior to the Effective Time represented outstanding
shares of Company Common Stock ("Company Certificates") a form letter
of transmittal (which shall specify that delivery shall be effective,
and risk of loss and title to the Company Certificate(s) shall pass,
only upon delivery of the Company Certificate(s) to the Exchange Agent)
and instructions for such holder's use in effecting the surrender of
the Company Certificates in exchange for certificates representing
shares of Parent Common Stock.
(b) As soon as practicable after the Effective Time, the
Exchange Agent shall distribute to holders of shares of Company Common
Stock, upon surrender to the Exchange Agent of one or more Company
Certificates for cancellation, together with a duly-executed letter of
transmittal, (i) one or more Parent certificates representing the
number of whole shares of Parent Common Stock into which the shares
represented by the Company Certificate(s) shall have been converted
pursuant to Section 1.3(a), and (ii) a bank check in the amount of cash
into which the shares represented by the Company Certificate(s) shall
have been converted pursuant to Section 1.5(f) (relating to fractional
shares), and the Company Certificate(s) so surrendered shall be
cancelled. In the event of a transfer of ownership of Company Common
Stock that is not registered in the transfer records of the Company, it
shall be a condition to the issuance of shares of Parent Common Stock
that the Company Certificate(s) so surrendered shall be properly
endorsed or be otherwise in proper form for transfer and that such
transferee shall (i) pay to the Exchange Agent any transfer or other
taxes required, or (ii) establish to the satisfaction of the Exchange
Agent that such tax has been paid or is not payable.
(c) Holders of Company Common Stock will be entitled to any
dividends or other distributions pertaining to the Parent Common Stock
received in exchange therefor that become payable to persons who are
holders of record of Parent Common Stock as of a record date on the
same date as or after the Effective Time, but only after they have
surrendered their Company Certificates for exchange. Subject to the
effect, if any, of applicable law, the Exchange Agent shall receive,
hold, and remit any such dividends or other distributions to each such
record holder entitled thereto, without interest, at the time that such
Company Certificates are surrendered to the Exchange Agent for
exchange. Holders of Company Common Stock will not be entitled,
however, to dividends or other distributions that become payable before
or after the Effective Time to persons who were holders of record of
Parent Common Stock as of a record date that is prior to the Effective
Time.
(d) All shares of Parent Common Stock issued upon the
surrender for exchange of Company Common Stock in accordance with the
terms hereof (including any cash paid for fractional shares pursuant to
Section 1.5(f) hereof) shall be deemed to have been issued in full
satisfaction of all rights pertaining to such shares of Company Common
Stock.
(e) After the Effective Time, there shall be no further
registration of transfers on the stock transfer books of the Surviving
Corporation of the shares of Company Common Stock that were outstanding
immediately prior to the Effective Time. If, after the Effective Time,
Company Certificates representing such shares are presented to the
Surviving Corporation, they shall be cancelled and exchanged as
provided in this Article 1. As of the Effective Time, the holders of
Company Certificates representing shares of Company Common Stock shall
cease to have any rights as shareholders of the Company, except such
rights, if any, as they may have pursuant to the MBCA. Except as
provided above, until such Company Certificates are surrendered for
exchange, each such Company Certificate shall, after the Effective
Time, represent for all purposes only the right to receive the number
of whole shares of Parent Common Stock into which the shares of Company
Common Stock shall have been converted pursuant to the Merger as
provided in Section 1.3(a) hereof and the right to receive the cash
value of any fraction of a share of Parent Common Stock as provided in
Section 1.5(f) hereof.
(f) No fractional shares of Parent Common Stock and no
certificates or scrip therefor, or other evidence of ownership thereof,
shall be issued upon the surrender for exchange of Company
Certificates, no dividend or other distribution of Parent shall relate
to any fractional share, and such fractional share interests shall not
entitle the owner thereof to vote or to any rights of a shareholder of
Parent. All fractional shares of Parent Common Stock to which a holder
of Company Common Stock immediately prior to the Effective Time would
otherwise be entitled, at the Effective Time, shall be aggregated if
and to the extent multiple Company Certificates of such holder are
submitted together to the Exchange Agent. If a fractional share results
from such aggregation, then (in lieu of such fractional share) the
Exchange Agent shall pay to each holder of shares of Company Common
Stock who otherwise would be entitled to receive such fractional share
of Parent Common Stock an amount of cash (without interest) determined
by multiplying (i) the Parent Average Stock Price by (ii) the
fractional share of Parent Common Stock to which such holder would
otherwise be entitled. Parent will make available to the Exchange Agent
any cash necessary for this purpose.
(g) In the event any Company Certificates shall have been
lost, stolen, or destroyed, the Exchange Agent shall issue in exchange
for such lost, stolen, or destroyed Company Certificates, upon the
making of an affidavit of that fact by the holder thereof, such shares
of Parent Common Stock and cash for fractional shares, if any, as may
be required pursuant to this Article 1; provided, however, that Parent
may, in its discretion and as a condition precedent to the issuance
thereof, require the owner of such lost, stolen, or destroyed Company
Certificate to deliver a bond in such sum as Parent may direct as
indemnity against any claim that may be made against Parent or the
Exchange Agent with respect to such Company Certificate alleged to have
been lost, stolen, or destroyed.
(h) Each person entitled to receive shares of Parent Common
Stock pursuant to this Article 1 shall receive together with such
shares the number of Parent preferred share purchase rights (pursuant
to the Rights Agreement dated as of June 27, 1991, between Parent and
Norwest Bank Minnesota, N.A., the "Parent Rights Plan") per share of
Parent Common Stock equal to the number of Parent preferred share
purchase rights associated with one share of Parent Common Stock at the
Effective Time.
1.6 Exchange of Merger Subsidiary Common Stock. From and after the
Effective Time, each outstanding certificate previously representing shares of
Merger Subsidiary Common Stock shall be deemed for all purposes to evidence
ownership of and to represent the number of shares of Surviving Corporation
Common Stock into which such shares of Merger Subsidiary Common Stock shall have
been converted. Promptly after the Effective Time, the Surviving Corporation
shall issue to Parent a stock certificate or certificates representing such
shares of Surviving Corporation Common Stock in exchange for the certificate or
certificates that formerly represented shares of Merger Subsidiary Common Stock,
which shall be cancelled.
1.7 Stock Options.
(a) Except as provided below with respect to the Company's
Employee Stock Purchase Plan, each option to purchase shares of Company
Common Stock that is outstanding at the Effective Time (a "Company
Option") shall, by virtue of the Merger and without any action on the
part of the holder thereof, be assumed by Parent (and a registration
statement on Form S-8 therefor shall be filed promptly after the
Effective Time) in such manner that Parent (i) is a corporation
"assuming a stock option in a transaction to which Section 424(a)
applies" within the meaning of Section 424 of the Code and the
regulations thereunder or (ii) to the extent that Section 424 of the
Code does not apply to any such Company Option, would be such a
corporation were Section 424 of the Code applicable to such Company
Option. From and after the Effective Time, all references to the
Company in the Company Options shall be deemed to refer to Parent
(other than for purposes of determining whether there has been a change
in control of the Company). The Company Options assumed by Parent shall
be exercisable upon the same terms and conditions as under the Company
Options (including provisions thereof, if any, relating to the
acceleration of vesting upon a change in control of the Company) except
that (i) such Company Options shall entitle the holder to purchase from
Parent the number of shares of Parent Common Stock (rounded to the
nearest whole number of such shares) that equals the product of the
Conversion Fraction multiplied by the number of shares of Company
Common Stock subject to such option immediately prior to the Effective
Time, and (ii) the option exercise price per share of Parent Common
Stock shall be an amount (rounded to the nearest full cent) equal to
the option exercise price per share of Company Common Stock in effect
immediately prior to the Effective Time divided by the Conversion
Fraction; provided, however, that in the case of any Company Option to
which Section 421 of the Code applies by reason of its qualification
under Section 422 of the Code ("incentive stock options"), the option
price, the number of shares purchasable pursuant to such option and the
terms and conditions of exercise of such options shall be determined in
order to comply with Section 424(a) of the Code. As promptly as
practicable after the Effective Time, Parent shall issue to each holder
of a Company Option a written instrument informing such holder of the
assumption by Parent of such Company Option.
(b) The current offering period in process as of the date of
this Agreement under the Company's Employee Stock Purchase Plan shall
continue and shares shall be issued to participants thereunder as
provided under, and subject to the terms and conditions of, such Plan;
provided, however, that if the Effective Time occurs prior to the
originally scheduled expiration of such current offering period on
September 30, 1998, then immediately prior to the Effective Time, such
current offering period under the Company's Employee Stock Purchase
Plan shall be ended, and each participant shall be deemed to have
purchased immediately prior to the Effective Time, to the extent of
payroll deductions accumulated by such participant as of such offering
period end, the number of whole shares of Company Common Stock at a per
share price determined pursuant to the provisions of the Company's
Employee Stock Purchase Plan, and each participant shall receive a cash
payment equal to the balance, if any, of such accumulated payroll
deductions remaining after such purchase of such shares. As of the
Effective Time, all such shares shall be converted in the manner
provided in Section 1.3. No offering periods under the Company's
Employee Stock Purchase Plan that are subsequent to the current
offering period in process as of the date of this Agreement shall be
commenced, and the Company's Employee Stock Purchase Plan and all
purchase rights thereunder shall terminate effective as of the
Effective Time.
1.8 Capitalization Changes. If, between the date of this Agreement and
the Effective Time, the outstanding shares of Parent Common Stock shall have
been changed into a different number of shares or a different class by reason of
any reclassification, recapitalization, split-up, combination, exchange of
shares, or stock dividend, the Conversion Fraction and all per-share price
amounts and calculations set forth in this Agreement shall be appropriately
adjusted.
1.9 Articles of Incorporation of the Surviving Corporation. The
Articles of Incorporation of Merger Subsidiary, as in effect immediately prior
to the Effective Time, shall be the Articles of Incorporation of the Surviving
Corporation until thereafter amended in accordance with applicable law;
provided, however, that upon the Effective Time, Article 1 of the Articles of
Incorporation of the Surviving Corporation shall be amended to read in its
entirety as follows: "The name of the corporation shall be Medtronic AVECOR
Cardiovascular, Inc."
1.10 Bylaws of the Surviving Corporation. The Bylaws of Merger
Subsidiary, as in effect immediately prior to the Effective Time, shall be the
Bylaws of the Surviving Corporation until thereafter amended in accordance with
applicable law.
1.11 Directors and Officers of the Surviving Corporation. The directors
and officers of Merger Subsidiary immediately prior to the Effective Time shall
be the directors and officers, respectively, of the Surviving Corporation until
their respective successors shall be duly elected and qualified.
ARTICLE 2
CLOSING
2.1 Time and Place. Subject to the satisfaction or waiver of the
provisions of Article 6, the closing of the Merger (the "Closing") shall take
place at 10:00 a.m., local time, on the day the Merger is approved by the
shareholders of the Company at the Company Shareholders Meeting (as defined in
Section 5.4 hereof), or as soon thereafter as all conditions to Closing have
been satisfied or waived, or on such other date and/or at such other time as
Parent and the Company may mutually agree. The date on which the Closing
actually occurs is herein referred to as the "Closing Date." The Closing shall
take place at the corporate headquarters offices of Parent, or at such other
place or in such other manner (e.g., by telecopy exchange of signature pages
with originals to follow by overnight delivery) as the parties hereto may agree.
2.2 Filings at the Closing. At the Closing, subject to the provisions
of Article 6, Parent, Merger Subsidiary, and the Company shall cause Articles of
Merger to be filed in accordance with the provisions of Section 302A.615 of the
MBCA, and take any and all other lawful actions and do any and all other lawful
things necessary to cause the Merger to become effective.
ARTICLE 3
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to Parent and Merger Subsidiary as
of the date hereof as follows:
3.1 Disclosure Schedule. As of the date hereof, the Company has not
completed its internal investigation and review for purposes of confirming and
verifying the representations and warranties of the Company contained in this
Agreement. On or prior to the close of business on the tenth business day after
the date hereof, the Company shall deliver to Parent a disclosure schedule ( the
"Disclosure Schedule") with each disclosure therein set forth in the section or
subsection which corresponds by number for purposes of exceptions to a
representation or warranty to the applicable section or subsection of this
Article 3. In the event that Parent determines that the Disclosure Schedule
contains information which in Parent's good faith, reasonable business judgment
adversely affects the value of the Company's business or prospects, then Parent
shall have the right, within 10 business days of the receipt of the full and
complete Disclosure Schedule, to terminate this Agreement as set forth in
Section 7.1(i) hereto.
3.2 Organization. The Company and each subsidiary of the Company
(referred to herein as a "Subsidiary") is a corporation duly organized, validly
existing, and in good standing under the laws of its respective jurisdiction of
incorporation and has all requisite corporate power and authority to own, lease,
and operate its properties and to carry on its business as now being conducted.
The Company and each Subsidiary is duly qualified and in good standing to do
business in each jurisdiction in which the property owned, leased, or operated
by it or the nature of the business conducted by it makes such qualification
necessary and where the failure to qualify could reasonably be expected to have
a Company Material Adverse Effect (as defined below). "Company Material Adverse
Effect" means any effect, change or event that, individually or in the aggregate
with all similar effects, changes or events, is or would reasonably be expected
to be material and adverse: (i) either before or immediately after the Effective
Time, to the business, properties, liabilities, results of operation, or
financial condition of the Company and its Subsidiaries, considered as a whole;
or (ii) to the Company's ability to perform any of its obligations under this
Agreement or to consummate the Merger; provided, however, that Company Material
Adverse Effect shall not be deemed to include the impact of actions or omissions
of the Company taken with the prior written consent of Parent in contemplation
of the transactions contemplated hereby, or the effects of the Merger (or any
announcement with respect thereto) and compliance with the provisions of this
Agreement on the operating performance or prospects of the Company and its
subsidiaries, including without limitation, any such loss of customer or
distributor relationships or employees following the announcement of the Merger.
The jurisdictions in which the Company and each Subsidiary are qualified are
listed on the Disclosure Schedule. The Company has heretofore delivered to
Parent complete and accurate copies of the Articles of Incorporation and Bylaws
of the Company and each Subsidiary, as currently in effect. Except to the extent
specifically disclosed on the Disclosure Schedule, or any entity in which the
Company owns, directly or indirectly, an equity interest of less than 1% of the
fair market value of such entity's outstanding equity securities, neither the
Company nor any Subsidiary, directly or indirectly, owns or controls or has any
capital, equity, partnership, participation, or other ownership interest in any
corporation, partnership, joint venture, or other business association or
entity.
3.3 Authorization. The Company has the requisite corporate power and
authority to execute and deliver this Agreement and, subject to obtaining the
necessary approval of its shareholders, the requisite corporate power and
authority to consummate the transactions contemplated hereby, and to file and
distribute the Proxy Statement/Prospectus (as defined in Section 5.4 hereof).
The execution and delivery of this Agreement by the Company and the consummation
of the transactions contemplated hereby have been duly and validly authorized
and approved by the Company's Board of Directors and, in accordance with Section
302A.673 of the MBCA, by the required committee of such Board of Directors, no
other corporate proceedings on the part of the Company or any Subsidiary are
necessary to authorize this Agreement, and, subject to obtaining the approval of
the Company's shareholders, no other corporate action on the part of the Company
or any Subsidiary is necessary to consummate the transactions contemplated
hereby. This Agreement has been duly and validly executed and delivered by the
Company and constitutes the valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, subject to laws of
general application relating to bankruptcy, insolvency, reorganization,
moratorium or other similar laws affecting creditors' rights generally and rules
of law governing specific performance, injunctive relief, or other equitable
remedies. To the Company's knowledge, each Agreement to Facilitate Merger and
Affiliate's Letter (as described in Sections 5.11 and 5.6) has been duly and
validly executed and delivered by the Company shareholder who is a party thereto
and constitutes the valid and binding obligation of such shareholder,
enforceable in accordance with its terms, subject to laws of general application
relating to bankruptcy, insolvency, reorganization, moratorium or other similar
laws affecting creditors' rights generally and rules of law governing specific
performance, injunctive relief, or other equitable remedies.
3.4 Capitalization. The authorized capital stock of the Company
consists of (i) 20,000,000 shares of Company Common Stock, par value $.01 per
share, of which 8,044,475 shares are issued and outstanding, and (ii) 2,000,000
shares of Company Preferred Stock, par value $.01 per share, including 200,000
shares of Series A Junior Preferred Stock, none of which are issued or
outstanding. Except as set forth on the Disclosure Schedule, all issued and
outstanding shares of capital stock of each Subsidiary are owned, beneficially
and of record, by the Company, free and clear of any Liens (as defined in
Section 3.15). All issued and outstanding shares of Company Common Stock have
been validly issued, are fully paid and nonassessable, and have not been issued
in violation of and are not currently subject to any preemptive rights. Except
as set forth on the Disclosure Schedule and except for options to purchase an
aggregate 832,250 shares of Company Common Stock at an aggregate exercise price
of $8,005,782 granted pursuant to the Company's 1991 Stock Incentive Plan and
1995 Non-Employee Director Option Plan (collectively, the "Company Option
Plans") listed, together with their respective exercise prices, on the
Disclosure Schedule, and except for the rights to purchase under the Company's
Employee Stock Purchase Plan shares of Company Common Stock (estimated to be
approximately 10,000 shares, at a per share price of $7.44, based on the current
contribution rates of the participants, as listed on the Disclosure Schedule,
and assuming the current Plan offering period in process as of the date of this
Agreement is ended on September 30, 1998 for this purpose), there are not any
outstanding or authorized subscriptions, options, warrants, calls, rights,
convertible securities, commitments, restrictions, arrangements, or any other
agreements of any character to which the Company or any Subsidiary is a party
that, directly or indirectly, (i) obligate the Company or any Subsidiary to
issue any shares of capital stock or any securities convertible into, or
exercisable or exchangeable for, or evidencing the right to subscribe for, any
shares of capital stock, (ii) call for or relate to the sale, pledge, transfer,
or other disposition or encumbrance by the Company or any Subsidiary of any
shares of its capital stock, or (iii) to the knowledge of the Company, relate to
the voting or control of such capital stock. The Disclosure Schedule sets forth
a complete and accurate list of all stock options, warrants, and other rights to
acquire Company Common Stock, including the name of the holder, the date of
grant, acquisition price, expiration date, number of shares, exercisability
schedule, and, in the case of options, the type of option under the Code. The
Disclosure Schedule also sets forth the contractual restrictions to which any
shares of Company Common Stock issued pursuant to the Company Option Plans or
otherwise are currently subject and also sets forth the restrictions to which
such shares will be subject immediately after the Effective Time, other than as
set forth in the Company Option Plans or stock option agreements thereunder. No
consent of holders or participants under the Company Option Plans or Employee
Stock Purchase Plan is required to carry out the provisions of Section 1.7. All
actions, if any, required on the part of the Company under the Company Option
Plans or Employee Stock Purchase Plan to allow for the treatment of Company
Options and the Employee Stock Purchase Plan as is provided in Section 1.7, has
been, or prior to the Closing will be, validly taken by the Company, and the
Company will not from and after the date hereof allow any increase in the rate
of a participant's contributions to the Employee Stock Purchase Plan, any new
enrollments or re-enrollments in the current offering period in process as of
the date of this Agreement under such Plan or the commencement of any offering
periods under such Plan subsequent to the current offering period in process as
of the date of this Agreement.
3.5 Reports and Financial Statements. The Company has filed all forms,
reports, registration statements, and documents required to be filed by it with
the Securities and Exchange Commission ("SEC") since January 1, 1995 (such
forms, reports, registration statements, and documents, together with any
amendments thereto, are referred to as the "Company SEC Filings"). As of their
respective dates, the Company SEC Filings (i) complied as to form in all
material respects with the applicable requirements of the Securities Act of 1933
and the rules and regulations thereunder (the "1933 Act") and the Securities
Exchange Act of 1934 and the rules and regulations thereunder (the "1934 Act"),
as the case may be, and (ii) did not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary
to make the statements made therein, in light of the circumstances under which
they were made, not misleading. The audited financial statements and unaudited
interim financial statements included or incorporated by reference in the
Company SEC Filings, including but not limited to the Company's audited
financial statements at and for the year ended December 31, 1997 (the "Company
1997 Financials"), (i) were prepared in accordance with generally accepted
accounting principles applied on a consistent basis during the periods involved
(except as may be indicated therein or in the notes thereto), subject, in the
case of unaudited interim financial statements, to the absence of notes and to
year-end adjustments, (ii) complied as of their respective dates in all material
respects with applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto, and (iii) fairly presented the
consolidated financial position of the Company as of the dates thereof and the
income, cash flows, and changes in shareholders' equity for the periods
involved. The statements of earnings included in the audited or unaudited
interim financial statements in the Company SEC Filings do not contain any items
of special or nonrecurring income or any other income not earned in the ordinary
course of business, except as expressly specified in the applicable statement of
operations or notes thereto. Prior to the date hereof, the Company has delivered
to Parent complete and accurate copies of all Company SEC Filings since January
1, 1995. The Company has also delivered to Parent complete and accurate copies
of all statements on Schedule 13D and Schedule 13G known to the Company to have
been filed with the SEC since January 1, 1997, with respect to capital stock of
the Company. Since January 1, 1997, the Company has filed in a timely manner all
reports required to be filed by it pursuant to Sections 13, 14, or 15(d) of the
1934 Act.
3.6 Absence of Undisclosed Liabilities. Except to the extent
specifically disclosed on the Disclosure Schedule, neither the Company nor any
Subsidiary has any liabilities or obligations of any nature (whether absolute,
accrued, contingent, or otherwise) which would have a Company Material Adverse
Effect except (a) liabilities or obligations that are accrued or reserved
against in the audited consolidated balance sheet of the Company as of December
31, 1997 contained in the Company 1997 Financials (the "Company Audited Balance
Sheet") or in the unaudited consolidated balance sheet of the Company as of
March 31, 1998 contained in the Company's Quarterly Report on Form 10-Q for the
fiscal quarter ended March 31, 1998 (the "Company Interim Balance Sheet"), and
(b) liabilities or obligations disclosed in this Agreement.
3.7 Consents and Approvals. Except for (i) any applicable requirements
of the 1933 Act, the 1934 Act, state securities laws, the Hart-Scott-Rodino
Antitrust Improvements Act of 1976 and the regulations thereunder (the "HSR
Act"), and the antitrust, competition, foreign investment, or similar laws of
any foreign countries or supranational commissions or boards that require
pre-merger notifications or filings with respect to the Merger (collectively,
"Foreign Merger Laws"), (ii) approval by the Company's shareholders, (iii) the
filing and recordation of appropriate merger documents as required by the MBCA,
(iv) compliance with Sections 302A.471 and 302A.473 of the MBCA regarding
dissenters' rights, or (v) any items disclosed on the Disclosure Schedule, the
execution and delivery of this Agreement and the Stock Option Agreement by the
Company, and, to the Company's knowledge, the execution and delivery of the
Agreements to Facilitate Merger, and the consummation of the transactions
contemplated hereby and thereby will not: (a) violate any provision of the
Articles of Incorporation or Bylaws of the Company or any Subsidiary; (b)
violate any statute, rule, regulation, order, or decree of any federal, state,
local, or foreign body or authority (including, but not limited to, the Food and
Drug Administration (the "FDA") or any nongovernmental self-regulatory agency)
by which the Company or any Subsidiary or any of their respective properties or
assets may be bound; (c) require any filing with or permit, consent, or approval
of any federal, state, local, or foreign public body or authority (including,
but not limited to, the FDA or any nongovernmental self-regulatory agency); or
(d) result in any violation or breach of, or constitute (with or without due
notice or lapse of time or both) a default under, result in the loss of any
material benefit under, or give rise to any right of termination, cancellation,
increased payments, or acceleration under, or result in the creation of any Lien
(as defined in Section 3.15) on any of the properties or assets of the Company
or any Subsidiary under, any of the terms, conditions, or provisions of any
note, bond, mortgage, indenture, license, franchise, permit, authorization,
agreement, or other instrument or obligation to which the Company or any
Subsidiary is a party, or by which it or any of its properties or assets may be
bound, except, (x) in the cases of clauses (b) or (c), where such violation,
failure to make any such filing or failure to obtain such permit, consent or
approval, would not prevent or delay consummation of this Merger or otherwise
prevent the Company from performing its obligations under this Agreement and
would not have a Company Material Adverse Effect, and (y) in the case of clause
(d), for any such violations, breaches, defaults, or other occurrences that
would not prevent or delay consummation of any of the transactions contemplated
hereby in any material respect, or otherwise prevent the Company from performing
its obligations under this Agreement in any material respect, and would not have
a Company Material Adverse Effect.
3.8 Compliance with Laws. Except to the extent specifically disclosed
on the Disclosure Schedule, all activities of the Company and each Subsidiary
have been, and are currently being, conducted in compliance with all applicable
federal, state, local, and foreign laws, ordinances, regulations,
interpretations, judgments, decrees, injunctions, permits, licenses,
certificates, governmental requirements (including, but not limited to FDA Good
Manufacturing Practices), orders, and other similar items of any court or other
governmental entity (including, but not limited to, those of the FDA or any
nongovernmental self-regulatory agency), the failure to comply with which could
reasonably be expected to have a Company Material Adverse Effect. The Company
and each Subsidiary has timely filed or otherwise provided all registrations,
reports, data, and other information and applications with respect to its
medical device, pharmaceutical, consumer, health care, and other governmentally
regulated products (the "Regulated Products") required to be filed with or
otherwise provided to the FDA or any other federal, state, local, or foreign
governmental authorities with jurisdiction over the manufacture, use, or sale of
the Regulated Products, and all regulatory licenses or approvals in respect
thereof are in full force and effect, except where the failure to file timely
such registrations, reports, data, information, and applications or the failure
to have such licenses and approvals in full force and effect would not have a
Company Material Adverse Effect.
3.9 Litigation. Except to the extent specifically disclosed on the
Disclosure Schedule, to the Company's knowledge, no investigation or review by
any federal, state, local, or foreign body or authority (including, but not
limited to, the FDA or any nongovernmental self-regulatory agency) with respect
to the Company or any Subsidiary is pending or threatened, nor has any such body
or authority (including, but not limited to, the FDA or any nongovernmental
self-regulatory agency) indicated to the Company or any Subsidiary an intention
to conduct the same. Except to the extent specifically disclosed on the
Disclosure Schedule, there are no claims, actions, suits, or proceedings by any
private party that could reasonably be expected to involve individually an
amount in excess of $50,000 or collectively an aggregate amount in excess of
$200,000, or by any governmental body or authority (including, but not limited
to, the FDA or any nongovernmental self-regulatory agency), against or affecting
the Company or any Subsidiary, pending or, to the knowledge of the Company,
threatened at law or in equity, or before any federal, state, local, foreign, or
other governmental department, commission, board, bureau, agency, or
instrumentality (including, but not limited to, the FDA or any nongovernmental
self-regulatory agency).
3.10 Absence of Material Adverse Changes. Except to the extent
specifically disclosed in the Disclosure Schedule, since December 31, 1997 there
has not been any (a) change or circumstance that could reasonably be expected to
have a Company Material Adverse Effect; (b) action by the Company or any
Subsidiary that, if taken on or after the date of this Agreement, would require
the consent or approval of Parent pursuant to Section 5.1 hereof, except for
actions as to which consent or approval has been given as provided therein or
actions prior to March 31, 1998; (c) damage, destruction, or loss, whether or
not covered by insurance, that could reasonably be expected to have a Company
Material Adverse Effect; (d) change by the Company or any Subsidiary in
accounting methods or principles used for financial reporting purposes, except
as required by a change in generally accepted accounting principles and
concurred with by the Company's independent public accountants; or (e)
agreement, whether in writing or otherwise, to take any action described or
referenced in this Section 3.10.
3.11 Environmental Laws and Regulations. The Disclosure Schedule
completely and accurately sets forth the following: (a) a list of all
above-ground storage tanks or underground storage tanks for Hazardous Materials
(as defined below) on real property now or at any time in the past owned,
leased, or occupied by the Company or any Subsidiary (such real property
referred to in this section as the "Real Property"); (b) the identity of any
Hazardous Materials (as defined below) used, generated, transported or disposed
of by the Company or any Subsidiary now or at any time in the past, together
with a brief description and location of each activity using such Hazardous
Materials; (c) a summary of the identity of, to the Company's knowledge, any
Hazardous Materials that have been disposed of or found on, above or below any
Real Property; and (d) a list of all reports, studies, and tests in the
possession of the Company or any Subsidiary or initiated by the Company or any
Subsidiary pertaining to the existence of Hazardous Materials on, above, or
below any Real Property or any property adjoining or which could reasonably be
expected to affect the Real Property, or concerning compliance with or liability
under the Regulations (as defined below). The Company has heretofore delivered
to Parent complete and accurate copies of such reports, studies, and tests.
The Company and each Subsidiary have obtained, and maintained in full
force and effect, all required environmental permits and other governmental
approvals and are in compliance with all applicable Regulations (as defined
below), except where the failure to so obtain and maintain or to be in
compliance would not have a Company Material Adverse Effect. Neither the Company
nor any Subsidiary (i) has received a written notice or Claim (as defined below)
alleging potential liability under any of the Regulations or alleging a
violation of the Regulations or (ii) has any knowledge that such a notice or
Claim may be issued in the future. Neither the Company nor any Subsidiary has
any knowledge of any notices to or Claims against any persons, alleging
potential liability under any of the Regulations with respect to the Real
Property or any adjoining properties or which could reasonably be expected to
affect the Real Property. Neither the Company nor any Subsidiary (i) has been or
is presently subject to or, to the knowledge of the Company, threatened with any
administrative or judicial proceeding pursuant to the Regulations, or (ii) has
any information that it may be subject to or, to the knowledge of the Company,
threatened with such a proceeding in the future. Neither the Company nor any
Subsidiary has knowledge of any conditions or circumstances that could
reasonably be expected to result in the determination of liability against the
Company or any Subsidiary relating to environmental matters that would have a
Company Material Adverse Effect, including, but not limited to, any Claim
arising from past or present environmental practices with respect to Hazardous
Materials, the Real Property, or any disposal sites. To the knowledge of the
Company, and except as allowed under applicable Laws or Regulations, no
Hazardous Materials have been or are threatened to be discharged, emitted, or
released into the air, water, soil, or subsurface at or from the Real Property
by the Company.
For purposes of this Section 3.11, the following terms shall have the
following meanings: (i) "Hazardous Materials" means asbestos, urea formaldehyde,
polychlorinated biphenyls, nuclear fuel or materials, chemical waste,
radioactive materials, explosives, known human carcinogens, petroleum products
or other substances or materials listed, identified, or designated as toxic or
hazardous or as a pollutant or contaminant in, or the use, release or disposal
of which is regulated by, the Regulations; (ii) "Regulations" means the
Comprehensive Environmental Response Compensation and Liability Act ("CERCLA")
as amended by the Superfund Amendments and Reauthorization Act of 1986 ("SARA"),
42 U.S.C. ss.ss. 9601 et seq.; the Federal Resource Conservation and Recovery
Act of 1976 ("RCRA"), 42 U.S.C. ss.ss. 6901 et seq.; the Clean Water Act, 33
U.S.C. ss.ss. 1321 et seq.; the Clean Air Act, 42 U.S.C. ss.ss. 7401 et seq.,
and any other federal, state, county, local, foreign, or other governmental
statute, regulation, or ordinance, as adopted and in effect as of the date
hereof, that relates to or deals with employee safety and human health,
pollution, health, or the environment including, but not limited to, the use,
generation, discharge, transportation, disposal, recordkeeping, notification,
and reporting of Hazardous Materials; and (iii) "Claim" means any and all
claims, demands, causes of actions, suits, proceedings, administrative
proceedings, losses, judgments, decrees, debts, damages, liabilities, court
costs, penalties, attorneys' fees, and any other expenses incurred, assessed,
sustained or alleged by or against the Company or any Subsidiary.
3.12 Officers, Directors and Employees. Prior to the date hereof, the
Company has provided to Parent a list that completely and accurately sets forth
the name and current annual salary rate of each officer or exempt employee of
the Company or any Subsidiary whose total remuneration for the last fiscal year
was, or for the current fiscal year has been set at, in excess of $50,000,
together with a summary of the bonuses, commissions and additional compensation,
if any, paid or payable to such persons for the last fiscal year and proposed
for the current fiscal year. The Disclosure Schedule completely and accurately
sets forth (i) the names of all former employees whose employment with the
Company or any Subsidiary has terminated either voluntarily or involuntarily
during the preceding 12-month period; and (ii) the names of the officers (with
all positions and titles indicated) and directors of the Company and each
Subsidiary. No unfair labor practice complaint against the Company or any
Subsidiary is pending before the National Labor Relations Board, and there is no
labor strike, slowdown or stoppage pending or, to the knowledge of the Company,
threatened against or involving the Company or any Subsidiary. Since January 1,
1995, no unionizing efforts have, to the knowledge of the Company, been made by
employees of the Company or any Subsidiary, neither the Company nor any
Subsidiary is a party to or subject to any collective bargaining agreement, and
no collective bargaining agreement is currently being negotiated by the Company
or any Subsidiary. There is no material labor dispute pending or, to the
knowledge of the Company, threatened between the Company or any Subsidiary and
its employees.
3.13 Taxes. The Company has previously furnished to Parent complete and
accurate copies of all tax or assessment reports and tax returns (including any
applicable information returns) required by any law or regulation (whether
United States, foreign, state, local, or other jurisdiction) and filed by the
Company for each of the three fiscal years ended December 31, 1995, 1996, and
1997 and of all such returns filed separately by any Subsidiary for fiscal years
ended during or after 1995. The Company and each Subsidiary has filed, or has
obtained extensions to file (which extensions have not expired without filing),
all state, local, United States, foreign, or other tax reports and returns
required to be filed by any of them. The Company and each Subsidiary has duly
paid, or accrued on its books of account, all taxes (including estimated taxes)
shown as due on such reports and returns (or such extension requests), or
assessed against it, or that it is obligated to withhold from amounts owed by it
to any person. The liabilities and reserves for taxes reflected on the Company
Audited Balance Sheet or the Company Interim Balance Sheet are adequate to cover
all taxes payable by the Company and its Subsidiaries for all taxable periods
and portions thereof ending on or before the dates thereof. There are no Liens
(as defined in Section 3.14) for taxes upon any property or asset of the Company
or any Subsidiary. Neither the Company nor any Subsidiary is delinquent in the
payment of any tax assessment (including, but not limited to, any applicable
withholding taxes). None of the tax returns or reports for the tax periods ended
December 31, 1995, 1996, and 1997 have been audited by the Internal Revenue
Service (the "IRS") or by any other taxing authority. Further, to the knowledge
of the Company, except as set forth in the Disclosure Schedule, no state of
facts exists or has existed that could reasonably be expected to subject the
Company or any Subsidiary to an additional tax liability for any taxes
assessable by either the IRS or any separate state, local, foreign, or other
taxing authority with respect to any reports or returns filed on or before the
date hereof (other than extension requests for which returns have not been filed
as of the date hereof) that would have a Company Material Adverse Effect.
Neither the Company nor any Subsidiary has, with regard to any assets or
property held, acquired or to be acquired by any of them, filed a consent to the
application of Section 341(f)(2) of the Code. Except to the extent specifically
disclosed on the Disclosure Schedule, neither the Company nor any Subsidiary has
(i) received notification of any pending or proposed examination by either the
IRS or any state, local, foreign, or other taxing authority, (ii) received
notification of any pending or proposed deficiency by either the IRS or any
state, local, foreign, or other taxing authority, or (iii) granted any extension
of the limitations period applicable to any claim for taxes.
For the purposes of this Section 3.12, "tax" shall mean and include
taxes, additions to tax, penalties, interest, fines, duties, withholdings,
assessments, and charges assessed or imposed by any governmental authority,
including but not limited to all federal, state, county, local, and foreign
income, profits, gross receipts, import, ad valorem, real and personal property,
franchise, license, sales, use, value added, stamp, transfer, withholding,
payroll, employment, excise, custom, duty, and any other taxes, obligations and
assessments of any kind whatsoever; "tax" shall also include any liability
arising as a result of being (or ceasing to be) a member of any affiliated,
consolidated, combined, or unitary group as well as any liability under any tax
allocation, tax sharing, tax indemnity, or similar agreement.
3.14 Contracts. Except as set forth on the Disclosure Schedule, neither
the Company nor any Subsidiary (i) is a party to any collective bargaining
agreement or contract with any labor union, (ii) is a party to any written or
oral contract for the employment of any officer, individual employee or other
person on a full-time or consulting basis, or relating to severance pay for any
such person, (iii) is a party to any (A) written or oral agreement or
understanding to repurchase assets previously sold (or to indemnify or otherwise
compensate the purchaser in respect of such assets) or (B) agreement for the
sale of any capital asset, (iv) is a party to any contract, arrangement,
commitment or understanding (whether written or oral) which provides for future
payments by the Company in excess of $50,000 and is not terminable by the
Company nor any Subsidiary within 60 days without payment of a penalty or
premium, other than employment contracts, benefit plans and leases otherwise
disclosed in the Disclosure Schedule or listed as an exhibit in the Company SEC
Filings, (v) is a party to any independent sales representative, OEM, supply,
distribution, manufacturers' representative, dealer, licensing (except for
immaterial licenses, which include without limitation, licenses for
off-the-shelf software) joint development, joint venture, research and
development, or similar contract, (vi) is a party to any contract, arrangement,
commitment or understanding which is a material contract (as defined in Item
601(b)(10) of Regulation S-K of the SEC) to be performed after the date of this
Agreement that has not been filed or incorporated by reference in the Company
SEC Filings, (vii) is a party to any confidentiality agreement or any agreement
which prohibits the Company or the Subsidiary from freely engaging in any
business anywhere in the world, (viii) is a party to any agreement or indenture
relating to the borrowing of money, (ix) has guaranteed any obligation for
borrowed money, or (x) is a party to any agreement or contract that obligates
the Company to pay consequential damages. The Company and each Subsidiary has
performed all obligations required to be performed by it under any listed or
material contract, plan, agreement, understanding, or arrangement made or
obligation owed by or to the Company or any Subsidiary, except where the failure
would not have a Company Material Adverse Effect; there has not been any event
of default (or any event or condition which with notice or the lapse of time,
both or otherwise, would constitute an event of default) thereunder on the part
of the Company, any Subsidiary, or, to the Company's knowledge, any other party
to any thereof that would have a Company Material Adverse Effect; the same are
in full force and effect and valid and enforceable by the Company or its
Subsidiaries in accordance with their respective terms subject to laws of
general application relating to bankruptcy, insolvency, reorganization,
moratorium or other similar laws affecting creditors' rights generally and rules
or law governing specific performance, injunctive relief, and other equitable
remedies; and the performance of any such contracts, plans, agreements,
understandings, arrangements, or obligations would not have a Company Material
Adverse Effect.
3.15 Title to Properties; Liens. The Company and/or its Subsidiaries
have good and marketable title to all properties and assets reflected on the
Company Audited Balance Sheet or the Company Interim Balance Sheet or acquired
after the dates thereof (except for properties and assets sold or otherwise
disposed of in the ordinary course of business since the dates thereof), which
includes each asset the absence or unavailability of which would have a Company
Material Adverse Effect, subject only to (a) statutory Liens arising or incurred
in the ordinary course of business with respect to which the underlying
obligations are not delinquent, (b) with respect to personal property, the
rights of customers of the Company or any Subsidiary with respect to inventory
or work in progress under orders or contracts entered into by the Company or any
Subsidiary in the ordinary course of business, (c) Liens reflected on the
Company Audited Balance Sheet or the Company Interim Balance Sheet, (d) Liens
for taxes not yet delinquent, and (e) and defects in title that would not have a
Company Material Adverse Effect. The term "Lien" as used in this Agreement means
any mortgage, pledge, security interest, encumbrance, lien, claim, or charge of
any kind. All properties and assets purported to be leased by the Company or any
Subsidiary are subject to valid and effective leases that are in full force and
effect, and there does not exist, and the Merger will not result in, any default
or event that with notice or lapse of time, or both or otherwise, would
constitute a default under any such leases which would have a Company Material
Adverse Effect. The properties and assets of the Company and each Subsidiary are
in good working condition.
3.16 Permits, Licenses, Etc. Except as specifically disclosed on the
Disclosure Schedule, the Company and each Subsidiary has all rights, permits,
certificates, licenses, consents, franchises, approvals, registrations, and
other authorizations necessary to sell its products and services and otherwise
carry on and conduct its business and to own, lease, use, and operate its
properties and assets at the places and in the manner now conducted and
operated, except those the absence of which would not have a Company Material
Adverse Effect. Neither the Company nor any Subsidiary has received any notice
or claim pertaining to the failure to obtain any permit, certificate, license,
franchise, approval, registration, or other authorization required by any
federal, state, local, or foreign body or authority (including, but not limited
to, any nongovernmental self-regulatory agency) except for any such notice or
claim regarding any such failure that would not have a Company Material Adverse
Effect, nor has the Company or any Subsidiary received any notice or claim
pertaining to the failure to obtain any permit, certificate, license, franchise,
approval, registration, or other authorization from the FDA or any similar
foreign regulatory agency.
3.17 Intellectual Property Rights. The Disclosure Schedule contains a
complete and accurate list of all patents, trademarks, trade names, service
marks, and all applications for or registrations of any of the foregoing that
the Company uses in its business (other than generally available computer
software) as to which the Company or any Subsidiary is the owner or a licensee
(indicating whether such license is exclusive or nonexclusive). To the knowledge
of the Company and except as disclosed on the Disclosure Schedule, the Company
and each Subsidiary exclusively owns, free and clear of any Lien (as defined in
Section 3.14), or is exclusively (unless otherwise indicated in the Disclosure
Schedule) licensed to use, all patents, trademarks, trade names, service marks,
applications for or registrations of any of the foregoing, processes,
inventions, designs, technology, formulas, computer software programs, know-how,
and trade secrets used in or necessary for the conduct of its respective
business as currently conducted or proposed to be conducted and where the lack
of ownership or such license would have a Company Material Adverse Effect (the
"Company Intellectual Property"). Except to the extent specifically disclosed on
the Disclosure Schedule, no claim has been asserted or, to the knowledge of the
Company, threatened by any person, and, to the Company's knowledge, its patent
counsel has not concluded that any claim exists, with respect to the Company's
ownership of the Company Intellectual Property or challenging or questioning the
validity or effectiveness of any license or agreement to which the Company is a
party with respect thereto. To the knowledge of the Company, neither the use of
the Company Intellectual Property by the Company or any Subsidiary in the
present or planned conduct of its business nor any product or service of the
Company or any Subsidiary infringes on the intellectual property rights of any
person. No current or former shareholder, employee, or consultant of the Company
or any Subsidiary has any material rights in or to any of the Company
Intellectual Property. All Company Intellectual Property listed on the
Disclosure Schedule has the status indicated therein and all applications are
still pending in good standing and have not been abandoned. Except to the extent
disclosed on the Disclosure Schedule: (i) to the Company's knowledge, patents
included within the Company Intellectual Property are valid and have not been
challenged in any judicial or administrative proceeding; (ii) the Company and
each Subsidiary have made all statutorily required filings, if any, to record
their interests, and taken reasonable actions to protect their rights, in the
Company Intellectual Property, where the failure to make any such filing, record
such interest or take such other actions could reasonably be expected to have a
Company Material Adverse Effect; (iii) to the knowledge of the Company, no
person or entity nor such person's or entity's business or products has
infringed or misappropriated any Company Intellectual Property or currently is
infringing or misappropriating any Company Intellectual Property; and (iv) no
other person or entity has any right to receive or any obligation to pay a
royalty with respect to any Company Intellectual Property or any product or
service of the Company or any Subsidiary.
3.18 Benefit Plans.
(a) Except to the extent specifically disclosed on the
Disclosure Schedule, neither the Company nor any Subsidiary sponsors,
maintains, contributes to, or has sponsored, maintained, or contributed
to or been required to contribute to, any "employee pension benefit
plan" ("Pension Plan"), as such term is defined in Section 3(2) of the
Employee Retirement Income Security Act of 1974, as amended ("ERISA"),
including, solely for the purpose of this subsection, a plan excluded
from coverage by Section 4(b)(5) of ERISA. No failure to comply with
applicable provisions of ERISA, the Code and other applicable law in
connection with any Pension Plan presently maintained by the Company or
any Subsidiary could reasonably be expected to have a Company Material
Adverse Effect.
(b) Neither the Company nor any Subsidiary sponsors,
maintains, contributes to, or has sponsored, maintained, or contributed
to or been required to contribute to, any Pension Plan that is a
"Multiemployer Plan" within the meaning of Section 4001(a)(3) of ERISA.
(c) Except to the extent specifically disclosed on the
Disclosure Schedule, neither the Company nor any Subsidiary sponsors,
maintains, contributes to, or has sponsored, maintained, contributed
to, or been required to contribute to, any "employee welfare benefit
plan" ("Welfare Plan"), as such term is defined in Section 3(1) of
ERISA, whether insured or otherwise. No failure to comply with
applicable provisions of ERISA, the Code and other applicable law,
including, but not limited to, Section 4980B of the Code and Part 6 of
Subtitle B of Title I of ERISA, in connection with any Welfare Plan
presently maintained by the Company or any Subsidiary could reasonably
be expected to have a Company Material Adverse Effect. Neither the
Company nor any Subsidiary has established or contributed to any
"voluntary employees' beneficiary association" within the meaning of
Section 501(c)(9) of the Code.
(d) Except to the extent specifically disclosed on the
Disclosure Schedule, neither the Company nor any Subsidiary sponsors,
maintains, or contributes to, or has sponsored, maintained, or
contributed to, a "self-insured medical reimbursement plan" within the
meaning of Section 105(h) of the Code and the regulations thereunder.
(e) Except to the extent specifically disclosed on the
Disclosure Schedule, neither the Company nor any Subsidiary currently
maintains or contributes to any oral or written bonus, profit-sharing,
compensation (incentive or otherwise), commission, stock option, or
other stock-based compensation, retirement, severance, change of
control, vacation, sick or parental leave, dependent care, deferred
compensation, cafeteria, disability, hospitalization, medical, death,
retiree, insurance, or other benefit or welfare or other similar plan,
policy, agreement, trust, fund, or arrangement providing for the
remuneration or benefit of all or any employees or shareholders or any
other person, that is neither a Pension Plan nor a Welfare Plan
(collectively, the "Compensation Plans").
(f) To the knowledge of the Company, neither any Pension Plans
or Welfare Plans nor any trust created or insurance contract issued
thereunder nor any trustee, fiduciary, custodian, or administrator
thereof, nor any officer, director, or employee of the Company or any
Subsidiary, custodian, or any other "disqualified person" within the
meaning of Section 4975(e)(2) of the Code, or "party in interest"
within the meaning of Section 3(14) of ERISA, with respect to any such
plan has engaged in any act or omission that could reasonably be
expected to result in a Company Material Adverse Effect in connection
with a liability for breach of fiduciary duties under ERISA or a tax or
penalty imposed by Section 502 of ERISA.
(g) Except to the extent specifically disclosed on the
Disclosure Schedule, (i) full and timely payment has been made of all
amounts that the Company or any Subsidiary is required, under
applicable law, with respect to any Pension Plan, Welfare Plan, or
Compensation Plan, or any agreement relating to any Pension Plan,
Welfare Plan, or Compensation Plan, to have paid as a contribution to
each Pension Plan, Welfare Plan, or Compensation Plan, (ii) to the
extent required by generally accepted accounting principles, the
Company has made adequate provisions for reserves to meet contributions
that have not been made because they are not yet due under the terms of
any Pension Plan, Welfare Plan, or Compensation Plan or related
agreements, (iii) there will be no change on or before the Closing Date
in the operation of any Pension Plan, Welfare Plan, or Compensation
Plan or documents under which any such plan is maintained that will
result in an increase in the benefit liabilities under such plan,
except as may be required by law or as provided by the terms of the
Pension Plan, Welfare Plan, Compensation Plan or document in effect on
the date of this Agreement, to the extent disclosed in or attached to
the Disclosure Schedule, (iv) the IRS has issued favorable
determination letters with respect to all Company and Subsidiary
Pension Plans that are intended to be qualified under Section 401(a) of
the Code, and (v) the Company has made available to Parent complete and
accurate copies of all Pension Plans, Welfare Plans, Compensation
Plans, and related agreements, annual reports (Form 5500), favorable
determination letters, current summary plan descriptions, and all
employee handbooks or manuals.
(h) Except to the extent specifically disclosed on the
Disclosure Schedule, the execution of, and performance of the
transactions contemplated in, this Agreement will not (either alone or
upon the occurrence of any additional or subsequent events) result in
forgiveness of indebtedness or an increase in benefits or result in the
acceleration of vesting, funding, benefit accruals or benefit payments
under any Pension Plan, Welfare Plan or Compensation Plan. Except to
the extent specifically disclosed on the Disclosure Schedule, no amount
that could reasonably be expected to be received (whether in cash or
property or the vesting of property) by any employee, officer, or
director of the Company or any of its affiliates who is a "disqualified
individual" (as such term is defined in proposed Treasury Regulation
Section 1.280G-1) under any Pension Plan, Welfare Plan, or Compensation
Plan currently in effect as a result of any of the transactions
contemplated by this Agreement would be an "excess parachute payment"
(as such term is defined in Section 280G(b)(1) of the Code).
3.19 Minute Books. The minute books of the Company and the
Subsidiaries, as previously made available to Parent and its representatives,
contain records of all actions taken at all meetings of and corporate actions or
written consents by the shareholders, Boards of Directors, and committees of the
Boards of Directors of the Company and the Subsidiaries, except for the absence
of such records as would not have a Company Material Adverse Effect.
3.20 Insurance Policies. The Disclosure Schedule sets forth a complete
and accurate list of all policies of insurance (with copies attached) maintained
by the Company or any Subsidiary with respect to any of its officers, directors,
employees, shareholders, agents, properties, buildings, machinery, equipment,
furniture, fixtures or operations and a description of each claim made in excess
of $5,000 by the Company or any Subsidiary during the three-year period
preceding the date hereof under any such policy of insurance. All such policies
of insurance are in full force and effect.
3.21 Bank Accounts. The Disclosure Schedule sets forth a list of each
bank, broker, or other depository with which the Company or any Subsidiary has
an account or safe deposit box, the names and numbers of such accounts or boxes
and the names of all persons authorized to draw thereon or execute transactions.
3.22 Powers of Attorney. The Disclosure Schedule sets forth the names
of all persons, if any, holding powers of attorney from the Company or any
Subsidiary and a description of the scope of each such power of attorney. The
Company has delivered to Parent prior to the date hereof complete and accurate
copies of all such powers of attorney.
3.23 Product Liability Claims. Except to the extent specifically
disclosed on the Disclosure Schedule, during the three-year period preceding the
date hereof neither the Company nor any Subsidiary has received a claim for or
based upon breach of product warranty (other than warranty service and repair
claims in the ordinary course of business not material in amount or
significance), strict liability in tort, negligent manufacture of product,
negligent provision of services or any other allegation of liability, including
or resulting in, but not limited to, product recalls, arising from the
materials, design, testing, manufacture, packaging, labeling (including
instructions for use), or sale of its products or from the provision of services
(hereafter collectively referred to as "Product Liability").
3.24 Warranties. The terms of all product and service warranties and
product return, sales credit, discount, warehouse allowance, advertising
allowance, demo sales, and credit policies of the Company and each Subsidiary
are specifically set forth on the Disclosure Schedule. The Company has attached
to the Disclosure Schedule complete and accurate copies of all such warranties
and policies.
3.25 Inventories. Except as specifically set forth on the Disclosure
Schedule, all inventories of the Company and its Subsidiaries consist of items
of merchantable quality and quantity usable or salable in the ordinary course of
business, are salable at prevailing market prices that are not less than the
book value amounts thereof or the price customarily charged by the Company or
the applicable Subsidiary therefor, conform to the specifications established
therefor, and have been manufactured in accordance with applicable regulatory
requirements, except to the extent that the failure of such inventories so to
consist, be saleable, conform, or be manufactured would not have a Company
Material Adverse Effect. Except as specifically set forth on the Disclosure
Schedule, the quantities of all inventories, materials, and supplies of the
Company and each Subsidiary (net of the obsolescence reserve therefor shown on
the Company Interim Balance Sheet and determined in the ordinary course of
business consistent with past practice) are not obsolete, damaged, slow-moving,
defective, or excessive, and are reasonable and balanced in the circumstances of
the Company and its Subsidiaries, except to the extent that the failure of such
inventories to be in such conditions would not have a Company Material Adverse
Effect. The Disclosure Schedule sets forth a true and complete list of the
addresses of all warehouses or other facilities in which inventories of the
Company or any Subsidiary are located.
3.26 Relations with Suppliers and Customers. Since January 1, 1995, no
current supplier of the Company or any Subsidiary has cancelled any contract or
order for provision of, and, to the knowledge of the Company, there has been no
threat by any such supplier not to provide, raw materials, products, supplies,
or services to the businesses of the Company and its Subsidiaries either prior
to or following the Merger except for any cancellation or threat which would not
have a Company Material Adverse Effect. Except as specifically set forth on the
Disclosure Schedule, neither the Company nor any Subsidiary has, to the
knowledge of the Company, received any information from any customer that
accounted for more than 5% of the revenues of the Company and its Subsidiaries
during the last full fiscal year reasonably to the effect that such customer
intends to materially decrease the amount of business it does with the
businesses of the Company and its Subsidiaries either prior to or following the
Merger. The Disclosure Schedule lists each supplier to the Company or any
Subsidiary that is the sole source of a particular raw material, product,
supply, or service.
3.27 No Finders. No act of the Company or any Subsidiary has given or
will give rise to any claim against any of the parties hereto for a brokerage
commission, finder's fee, or other like payment in connection with the
transactions contemplated herein, except payments in the amounts specified on
the Disclosure Schedule to those parties identified thereon who have acted as a
finder for the Company or have been retained by the Company as financial
advisors pursuant to the agreements or other documents described in the
Disclosure Schedule, copies of which have been provided to Parent prior to the
date of this Agreement.
3.28 Proxy Statement. The Proxy Statement/Prospectus (as defined in
Section 5.4 hereof) and any amendments or supplements thereto will comply as to
form in all material respects with the provisions of the 1934 Act as amended,
and the rules and regulations promulgated thereunder, and none of the
information relating to the Company or its affiliates included or incorporated
therein or in any amendments or supplements thereto, or any schedules required
to be filed with the SEC in connection therewith, will, as of the date mailed to
the Company's shareholders and at the time of the Company Shareholders Meeting,
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading; provided, however, that no representation or warranty is made by the
Company with respect to information relating to Parent or any affiliate of
Parent.
3.29 Merger Filings. The information as to the Company and the
Subsidiaries or any of their affiliates or shareholders included in the
Company's filing, or submitted to Parent for inclusion in its filing, if any,
required to be submitted under the HSR Act or under any Foreign Merger Laws
shall be true, correct, and complete in all material respects and shall comply
in all material respects with the applicable requirements of the HSR Act, the
rules and regulations issued by the Federal Trade Commission pursuant thereto,
and the Foreign Merger Laws.
3.30 Fairness Opinion. The Company has received a written opinion from
Piper Jaffray, Inc. to the effect that, as of the date hereof, the consideration
to be received by the holders of Company Common Stock in the Merger is fair to
such holders from a financial point of view, and the Company will promptly
deliver a copy of such opinion to Parent.
3.31 State Takeover Laws; Rights Agreement.
(a) The Board of Directors of the Company and, in accordance
with Section 302A.673 of the MBCA, the required committee of such Board
of Directors have approved the transactions contemplated by this
Agreement, the Agreements to Facilitate Merger described in Section
5.11 hereof, and the Stock Option Agreement described in Section 5.17
hereof such that the provisions of Sections 302A.671 and 302A.673 of
the MBCA will not apply to this Agreement or the Agreements to
Facilitate Merger or the Stock Option Agreement or any of the
transactions contemplated hereby or thereby.
(b) The Company has taken all action and completed all
amendments, if any, necessary or appropriate so that (i) the Rights
Agreement dated as of June 26, 1996, as amended, between the Company
and Northwest Bank Minnesota, N.A. (the "Company Rights Agreement"), is
inapplicable to the transactions contemplated by the Agreements to
Facilitate Merger, the Stock Option Agreement and this Agreement, (ii)
the execution of this Agreement, the Stock Option Agreement, and the
Agreements to Facilitate Merger, and the consummation of the
transactions contemplated hereby and thereby, do not and will not
result in the ability of any person to exercise any Rights under the
Company Rights Agreement or enable or require the Rights to separate
from the shares of Company Common Stock to which they are attached or
to be triggered or become exercisable, or otherwise result in the
occurrence of a "Distribution Date" or "Stock Acquisition Date" (as
such terms are defined in the Company Rights Agreement), and (iii)
immediately prior to the Effective Time, the Rights under the Company
Rights Agreement shall, without any payment by the Company or Parent,
expire with neither the Company nor Parent having any obligations
under, and no holder of Rights having any rights under, the Rights or
the Company Rights Agreement.
ARTICLE 4
REPRESENTATIONS AND WARRANTIES
OF PARENT AND MERGER SUBSIDIARY
Parent and Merger Subsidiary hereby jointly and severally represent and
warrant to the Company as of the date hereof as follows:
4.1 Organization. Each of Parent and Merger Subsidiary is a corporation
duly organized, validly existing, and in good standing under the laws of the
state of Minnesota and has all requisite corporate power and authority to own,
lease, and operate its properties and to carry on its business as now being
conducted. Each of Parent and Merger Subsidiary is duly qualified and in good
standing to do business in each jurisdiction in which the property owned,
leased, or operated by it or the nature of the business conducted by it makes
such qualification necessary and where the failure to qualify could reasonably
be expected to have a Parent Material Adverse Effect (as defined below). "Parent
Material Adverse Effect" means any effect, change or event that, individually or
in the aggregate with all similar effects, changes or events, is or would
reasonably be expected to be material and adverse: (i) to the business,
properties, liabilities, results of operation, or financial condition of Parent
and its subsidiaries, considered as a whole, or (ii) to Parent's ability to
perform any of its obligations under this Agreement or to consummate the Merger.
4.2 Authorization. Each of Parent and Merger Subsidiary has the
requisite corporate power and authority to execute and deliver this Agreement
and to consummate the transactions contemplated hereby, and Parent has full
corporate power and authority to prepare, file, and distribute the Registration
Statement (as defined in Section 5.4 hereof). The execution and delivery of this
Agreement by Parent and Merger Subsidiary and the consummation of the
transactions contemplated hereby have been duly and validly authorized and
approved by the Boards of Directors of Parent and Merger Subsidiary and by
Parent as the sole shareholder of Merger Subsidiary, and no other corporate
proceedings on the part of Parent and Merger Subsidiary are necessary to
authorize this Agreement or to consummate the transactions contemplated hereby.
This Agreement has been duly and validly executed and delivered by each of
Parent and Merger Subsidiary and constitutes the valid and binding obligation of
Parent and Merger Subsidiary, enforceable against each of them in accordance
with its terms, subject to laws of general application relating to bankruptcy,
insolvency, reorganization, moratorium or other similar laws affecting
creditors' rights generally and rules of law governing specific performance,
injunctive relief, or other equitable remedies.
4.3 Capitalization. As of July 2, 1998, the authorized capital stock of
Parent consisted of (a) 800,000,000 shares of Common Stock with a par value of
$.10 per share, of which there were 469,350,541 shares issued and outstanding
and no shares held in Parent's treasury, and (b) 2,500,000 shares of Preferred
Stock with a par value of $1.00 per share, of which there were no shares issued
and outstanding. The authorized capital stock of Merger Subsidiary consists of
2,500 shares of Merger Subsidiary Common Stock, 100 of which are issued and
outstanding and owned by Parent. All issued and outstanding shares of Parent
Common Stock and Merger Subsidiary Common Stock are, and the shares of Parent
Common Stock to be issued and delivered in the Merger pursuant to Article 1
hereof shall be, at the time of issuance and delivery, validly issued, fully
paid, nonassessable, and free of preemptive rights. The shares of Parent Common
Stock to be issued and delivered in the Merger pursuant to Article 1 hereof
shall be registered under the 1933 Act and duly listed for trading on the NYSE,
subject to official notice of issuance.
4.4 Consents and Approvals. Except for (i) any applicable requirements
of the 1933 Act, the 1934 Act, state securities laws, the NYSE, the HSR Act, and
Foreign Merger Laws, (ii) the filing and recordation of appropriate merger
documents as required by the MBCA, and (iii) compliance with Sections 302A.471
and 302A.473 of the MBCA regarding dissenters' rights of the Company's
shareholders, the execution and delivery of this Agreement by Parent and Merger
Subsidiary and the consummation of the transactions contemplated hereby will
not: (a) violate any provision of the Articles of Incorporation or Bylaws of
Parent or Merger Subsidiary; (b) violate any statute, rule, regulation, order,
or decree of any public body or authority (including, but not limited to, the
FDA or any nongovernmental self-regulatory agency) by which Parent or any of its
subsidiaries or any of their respective properties or assets may be bound; (c)
require any filing with or permit, consent, or approval of any public body or
authority (including, but not limited to, the FDA or any nongovernmental
self-regulatory agency); or (d) result in any violation or breach of, or
constitute (with or without due notice or lapse of time or both) a default
under, result in the loss of any material benefit under, or give rise to any
right of termination, cancellation, increased payments, or acceleration under,
or result in the creation of any Lien on any of the properties or assets of
Parent or its subsidiaries under, any of the terms, conditions, or provisions of
any note, bond, mortgage, indenture, license, franchise, permit, agreement, or
other instrument or obligation to which Parent or any of its subsidiaries is a
party, or by which any of them or any of their respective properties or assets
may be bound, except (x) in the cases of clauses (b) or (c), where such
violation, failure to make any such filing or failure to obtain such permit,
consent or approval, would not prevent or delay consummation of this Merger or
otherwise prevent Parent from performing its obligations under the Agreement and
would not have a Parent Material Adverse Effect, and (y) in the case of clause
(d), for any such violations, breaches, defaults, or other occurrences that
would not prevent or delay consummation of any of the transaction contemplated
hereby in any material respect, or otherwise prevent Parent from performing its
obligations under this Agreement in any material respect, and would not have a
Parent Material Adverse Effect.
4.5 Reports; Financial Statements; Absence of Changes. Parent has filed
all forms, reports, registration statements, and documents required to be filed
by it with the SEC since January 1, 1995 (such forms, reports, registration
statements and documents, together with any amendments thereto, are referred to
as the "Parent SEC Filings"). As of their respective dates, the Parent SEC
Filings (i) complied as to form in all material respects with the applicable
requirements of the 1933 Act and the 1934 Act, as the case may be, and (ii) did
not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements made
therein, in light of the circumstances under which they were made, not
misleading. The audited financial statements and unaudited interim financial
statements included or incorporated by reference in the Parent SEC Filings (i)
were prepared in accordance with generally accepted accounting principles
applied on a consistent basis during the periods involved (except as may be
indicated therein or in the notes thereto), (ii) complied as of their respective
dates in all material respects with applicable accounting requirements and the
published rules and regulations of the SEC with respect thereto, and (iii)
fairly present the consolidated financial position of Parent as of the dates
thereof and the income, cash flows, and changes in shareholders' equity for the
periods involved. Except to the extent disclosed in Parent's subsequent filings
with the SEC or specifically disclosed on Schedule 4.5, since April 30, 1997,
there has not been any change or circumstance that would have a Parent Material
Adverse Effect or as of the date hereof any liabilities or obligations of any
nature (whether absolute, accrued, contingent or otherwise) that would have a
Parent Material Adverse Effect. Except to the extent disclosed in the Parent SEC
Filings or on Schedule 4.5, (i) to Parent's knowledge, there is no
investigation, review, claim, action, suit or proceeding by any federal, state,
local or foreign body or authority (including, but not limited to, the FDA or
any nongovernmental self-regulatory agency) or private party with respect to
Parent that could reasonably be expected to have a Parent Material Adverse
Effect, (ii) all activities of Parent and its subsidiaries have been, and are
currently being, conducted in compliance with all applicable federal, state,
local, and foreign laws, ordinances, regulations, interpretations, judgments,
decrees, injunctions, permits, licenses, certificates, governmental
requirements, orders and other similar items of any court or other governmental
entity (including, but not limited to, those of the FDA or any nongovernmental
self-regulatory agency), the failure to comply with which could reasonably be
expected to have a Parent Material Adverse Effect, (iii) Parent and each of its
subsidiaries has timely filed or otherwise provided all registrations, reports,
data, and other information and applications with respect to its Regulated
Products required to be filed with or otherwise provided to the FDA or any other
federal, state, local, or foreign governmental authorities with jurisdiction
over the manufacture, use or sale of the Regulated Products, and all regulatory
licenses or approvals in respect thereof are in full force and effect, except
for the failure to file timely such registrations, reports, data, information,
and applications or the failure to have such licenses and approvals in full
force and effect would not have a Parent Material Adverse Effect.
4.6 Registration Statement. The Registration Statement (as defined in
Section 5.4 hereof) and any amendments or supplements thereto will comply in all
material respects as to form with the 1933 Act, and none of the information
relating to Parent or its affiliates included or incorporated therein or in any
amendments or supplements thereto, or any schedules required to be filed with
the SEC in connection therewith, will, at the time the Registration Statement
becomes effective or as of the date of the Company Shareholders Meeting, contain
any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading; provided, however, that no representation or warranty is made by
Parent with respect to information relating to the Company or any affiliate of
the Company.
4.7 Merger Filings. The information as to Parent and Merger Subsidiary
or any of their affiliates or shareholders included in Parent's filing, or
submitted to the Company for inclusion in its filing, if any, required to be
submitted under the HSR Act or under any Foreign Merger Laws shall be true,
correct, and complete in all material respects and shall comply in all material
respects with the applicable requirements of the HSR Act, the rules and
regulations issued by the Federal Trade Commission pursuant thereto, and Foreign
Merger Laws.
4.8 No Finders. No act of Parent or Merger Subsidiary has given or will
give rise to any claim against any of the parties hereto for a brokerage
commission, finder's fee, or other like payment in connection with the
transactions contemplated herein.
ARTICLE 5
COVENANTS
5.1 Conduct of Business of the Company. Except as contemplated by this
Agreement or to the extent that Parent otherwise consents in writing, during the
period from the date of this Agreement to the Effective Time, the Company and
each Subsidiary will conduct its respective operations according to its ordinary
and usual course of business and consistent with past practice, and the Company
and each Subsidiary will use all reasonable efforts to preserve intact in all
material respects its respective business organizations, to maintain its present
and planned business, to keep available the services of its respective officers
and employees and to maintain satisfactory relationships with licensors,
licensees, suppliers, contractors, distributors, physicians, consultants,
customers, and others having business relationships with it; provided, however,
that the Company will not be required to make any payments or enter into or
amend any contractual arrangements or understandings to satisfy the foregoing
obligations. Without limiting the generality of the foregoing, and except as
otherwise expressly provided in or contemplated by this Agreement, prior to the
Effective Time, neither the Company nor any Subsidiary will, without the prior
written consent of Parent:
(a) amend its Articles of Incorporation or Bylaws;
(b) authorize for issuance, issue, sell, pledge, or deliver
(whether through the issuance or granting of additional options,
warrants, commitments, subscriptions, rights to purchase, or otherwise)
any stock of any class or any securities convertible into shares of
stock of any class (other than the issuance of the number of shares of
Company Common Stock indicated in Section 3.4 hereof upon the exercise
in accordance with the current terms of the stock options and other
rights listed in the Disclosure Schedule hereof as outstanding on the
date of this Agreement, and the actual number of shares issued for the
final offering period under the Company's Employee Stock Purchase Plan
in accordance with the Section 3.3 hereof);
(c) split, combine, or reclassify any shares of its capital
stock, declare, set aside, or pay any dividend or other distribution
(whether in cash, stock, or property or any combination thereof) in
respect of its capital stock; or redeem or otherwise acquire any shares
of its capital stock or other securities; or amend or alter any
material term of any of its outstanding securities;
(d) other than in the ordinary course of business and
consistent with past practice, create, incur, or assume any
indebtedness for borrowed money, or assume, guarantee, endorse, or
otherwise become liable or responsible (whether directly, contingently,
or otherwise) for the obligations of any other person, or make any
loans, advances or capital contributions to, or investments in, any
other person; or create, incur or assume any Lien on any material
asset;
(e) knowingly take any action that would have the effect of
jeopardizing the qualification of the Merger as a reorganization within
the meaning of Section 368(a)(2)(E) of the Code;
(f) (i) increase in any manner the compensation of any of its
directors, officers, employees, shareholders, or consultants, except in
the ordinary course of business and consistent with past practice or
consistent with existing contractual commitments, in each case to the
extent disclosed in the Disclosure Schedule or accelerate the payment
of any such compensation (whether or not any such acceleration is
consistent with past practice) other than as required by existing
contractual commitments to the extent disclosed in the Disclosure
Schedule; (ii) pay or accelerate or otherwise modify the payment,
vesting, exercisability, Company matching amount, or other feature or
requirement of any pension, retirement allowance, severance, change of
control, stock option, or other employee benefit not required by any
existing plan, agreement, or arrangement or by applicable law to any
such director, officer, employee, shareholder, or consultant, whether
past or present, except as determined by the Company to be necessary to
comply with applicable law or maintain tax-favored status (and any
nonmaterial changes incidental thereto); or (iii) except for normal
increases in the ordinary course of business in accordance with its
customary past practices or consistent with existing contractual
commitments, in each case to the extent disclosed in the Disclosure
Schedule, commit itself to any additional or increased pension,
profit-sharing, bonus, incentive, deferred compensation, stock
purchase, stock option, stock appreciation right, group insurance,
severance, change of control, retirement or other benefit, plan,
agreement, or arrangement, or to any employment or consulting
agreement, with or for the benefit of any person, or amend any of such
plans or any of such agreements in existence on the date hereof;
(g) except in the ordinary course of business and consistent
with past practice or pursuant to contractual obligations existing on
the date hereof, (i) sell, transfer, mortgage, or otherwise dispose of
or encumber any real or personal property, (ii) pay, discharge, or
satisfy any material claim, liability, or obligation (absolute,
accrued, contingent, or otherwise), or (iii) cancel any debts or waive
any claims or rights, which involve payments or commitments to make
payments that individually exceed $50,000 or, in the aggregate, exceed
$100,000;
(h) acquire or agree to acquire (i) by merging or
consolidating with, or by purchasing a substantial portion of the
assets of, or by any other manner, any portion of the assets of, or by
any other manner, any business of any corporation, partnership, joint
venture, association, or other business organization or division
thereof or (ii) any assets that are material, individually or in the
aggregate, to the Company, except as provided in subsection (i) below
and except purchases of inventory in the ordinary course of business
consistent with past practice;
(i) make or agree to make any new capital expenditure or
expenditures that, individually, is in excess of $50,000 or, in the
aggregate, are in excess of $100,000;
(j) enter into, amend, or terminate any joint ventures or any
other agreements, commitments, or contracts that, individually or in
the aggregate, are material to the Company or any Subsidiary (except
agreements, commitments, or contracts expressly provided for or
contemplated by this Agreement or for the purchase, sale, or lease of
goods, services, or properties in the ordinary course of business,
consistent with past practice), or otherwise make any material change
in the conduct of the business or operations of the Company or any
Subsidiary;
(k) enter into or terminate, or amend, extend, renew, or
otherwise modify (including, but not limited to, by default or by
failure to act) any distribution, OEM, independent sales
representative, noncompetition, licensing, franchise, research and
development, supply, or similar contract, agreement, or understanding
(except agreements, commitments, or contracts expressly provided for or
contemplated by this Agreement or for the purchase, sale, or lease of
goods, services, or properties in the ordinary course of business,
consistent with past practice);
(l) change in any material respect its credit policy as to
sales of inventories or collection of receivables or its inventory
consignment practices;
(m) remove or permit to be removed from any building,
facility, or real property any machinery, equipment, fixture, vehicle,
or other personal property or parts thereof, except in the ordinary
course of business;
(n) alter or revise its accounting principles, procedures,
methods, or practices, except as required by a change in generally
accepted accounting principles and concurred with by the Company's
independent public accountants;
(o) institute, settle, or compromise any claim, action, suit,
or proceeding pending or threatened by or against it involving amounts
in excess of $100,000, at law or in equity or before any federal,
state, local, foreign, or other governmental department, commission,
board, bureau, agency, or instrumentality (including, but not limited
to, the FDA or any nongovernmental self-regulatory agency);
(p) distribute or otherwise circulate any notices, directives,
or other communications directed to all or groups of customers,
vendors, employees, distributors, or others associated with its
business relating to the transactions contemplated hereby or to the
operation of business after completion of the Merger without consulting
with Parent, giving Parent reasonable opportunity to comment thereon,
and obtaining prior to distribution Parent's approval thereof, which
shall not unreasonably be withheld;
(q) knowingly take any action that would cause the condition
set forth in Section 6.2(a) not to be met; or
(r) agree, whether in writing or otherwise, to do any of the
foregoing.
provided, however, that in the event that the Company or any of its Subsidiaries
would be prohibited from taking any action by reason of this Section 5.1 without
the prior written consent of Parent, such action may nevertheless be taken if
the Company or any of its Subsidiaries is expressly required to do so by law and
the Company prior to taking such action informs Parent in writing of such
requirement.
5.2 No Solicitation. From the date hereof until the termination of this
Agreement, the Company will not and will cause its Subsidiaries and its and
their respective officers, directors, employees, representatives, agents, or
affiliates (including, but not limited to any investment banker, attorney, or
accountant retained by the Company or any Subsidiary), to not, directly or
indirectly, solicit, encourage, initiate, or participate in any way in
discussions or negotiations with, or knowingly provide any information to, any
corporation, partnership, person, or other entity or group (other than Parent or
any affiliate or agent of Parent) concerning any merger, sale or licensing of
any significant portion of the assets, sale of shares of capital stock
(including without limitation any proposal or offer to the Company's
shareholders), or similar transactions involving the Company or any Subsidiary
(an "Alternative Proposal"), or otherwise facilitate any effort or attempt to
make or implement an Alternative Proposal. The Company will promptly communicate
to Parent the terms of any proposal or inquiry that it has received or may
receive in respect of any such transaction or of any such information requested
from it or of any such negotiations or discussions being sought to be initiated
with the Company and may inform any third party who contacts the Company on an
unsolicited basis concerning an Alternative Proposal that the Company is
obligated hereunder to disclose such to Parent. Notwithstanding the foregoing,
this section shall not prohibit the Board of Directors of the Company from (i)
furnishing information to or entering into discussions or negotiations with, any
person or entity that makes an unsolicited bona fide Alternative Proposal, if,
and only to the extent that, (a) the Board of Directors of the Company
determines in good faith, after receipt of advice to such effect from outside
legal counsel, that such action is so required for the board of Directors to
comply with its fiduciary duties to shareholders imposed by law, (b) prior to
furnishing information to, or entering into discussions and negotiations with,
such person or entity, the Company promptly provides written notice to Parent to
the effect that it is furnishing information to, or entering into discussions or
negotiations with, such person or entity, and (c) the Company keeps Parent
informed of the status and all material terms and events with respect to any
such Alternative Proposal; and (ii) to the extent applicable, complying with
Rules 14d-9 and 14e-2 promulgated under the 1934 Act, as amended, with regard to
an Alternative Proposal. Nothing in this section shall (x) permit the Company to
terminate this Agreement (except as specifically provided in Article 7 hereof),
(y) permit the Company to enter into any agreement with respect to an
Alternative Proposal for as long as this Agreement remains in effect (it being
agreed that for as long as this Agreement remains in effect, the Company shall
not enter into any agreement with any person that provides for, or in any way
facilitates, an Alternative Proposal), or (z) affect any other obligation of the
Company under this Agreement while this Agreement remains in effect.
5.3 Access and Information. The Company shall afford to Parent, and to
Parent's accountants, officers, directors, employees, counsel, and other
representatives, reasonable access during normal business hours, from the date
hereof through the Effective Time, to all of its properties, books, contracts,
commitments, and records, and, during such period, the Company shall furnish
promptly to Parent all information concerning the Company's and its
Subsidiaries' businesses, prospects, properties, liabilities, results of
operations, financial condition, testing, clinicals, officers, employees,
investigators, distributors, customers, suppliers, and others having dealings
with the Company as Parent may reasonably request and reasonable opportunity to
contact and obtain information from such officers, employees, investigators,
distributors, customers, suppliers, and others having dealings with the Company
as Parent may reasonably request, subject, however, to limitations under
existing confidentiality agreements with other bidders with respect to prior
offers. During the period from the date hereof to the Effective Time, the
parties shall in good faith meet and correspond on a regular basis for mutual
consultation concerning the conduct of the Company's and the Subsidiaries'
businesses and, in connection therewith, Parent shall be entitled to have
employees or other representatives present at the offices of the Company and its
Subsidiaries to observe, and be kept informed concerning, the Company's and the
Subsidiaries' operations and business planning. Parent shall hold in confidence
all such nonpublic information as required and in accordance with the
confidentiality letter agreement dated June 2, 1998, between Parent and the
Company, as amended by the amendment to confidentiality letter agreement dated
the same date (the "Confidentiality Agreement").
5.4 Approval of Shareholders; Proxy Statement; Registration Statement.
(a) The Company shall take all action necessary in accordance
with Minnesota law and the Company's Articles of Incorporation and
Bylaws to cause a special meeting of the Company's shareholders (the
"Company Shareholders Meeting") to be duly called and held as soon as
reasonably practicable following the date upon which the Registration
Statement (as defined below) becomes effective for the purpose of
voting upon the Merger. The shareholder vote or consent required for
approval of the Plan of Merger and the Merger shall be no greater than
that set forth in the MBCA and the Company's Articles of Incorporation
as previously provided to Parent. Accordingly, the Company represents
and warrants that the affirmative vote of the holders of record of a
majority of the outstanding shares of Company Common Stock is all that
is necessary to obtain shareholder approval of the Plan of Merger and
the Merger. The Company shall use all reasonable efforts to obtain the
approval by the Company's shareholders of this Agreement, the Plan of
Merger, and the Merger. In accordance therewith, the Company shall,
with the cooperation of Parent, prepare and file, as soon as reasonably
practicable, a proxy statement/prospectus included as part of the
Registration Statement (such proxy statement/prospectus, together with
notice of meeting, form of proxy, and any letter or other materials to
the Company's shareholders included therein are referred to in this
Agreement as the "Proxy Statement/Prospectus"). The Company shall use
all reasonable efforts to cause the definitive Proxy
Statement/Prospectus to be mailed to the shareholders of the Company,
as soon as reasonably practicable following its effectiveness, with the
date of mailing as mutually determined by the Company and Parent. The
Company will, through its Board of Directors, recommend to its
shareholders approval of the Merger in the definitive Proxy
Statement/Prospectus.
(b) Parent shall, with the cooperation of the Company, prepare
and file, as soon as reasonably practicable, a registration statement
under the 1933 Act registering the shares of Parent Common Stock to be
issued in the Merger (the "Registration Statement"), which Registration
Statement shall include the Proxy Statement/Prospectus. Parent will use
all reasonable efforts to have the Registration Statement declared
effective by the SEC as promptly thereafter as practicable. Parent
shall also take any action required to be taken under state blue sky or
securities laws in connection with the issuance of Parent Common Stock
pursuant to the Merger. The Company shall furnish to Parent all
information concerning the Company and its Subsidiaries and the holders
of its capital stock, and shall take such other action and otherwise
cooperate, as Parent may reasonably request in connection with any such
action.
(c) Parent shall notify the Company promptly of the receipt of
the comments of the SEC and of any request by the SEC for amendments or
supplements to the Registration Statement and shall supply the Company
with copies of all correspondence with the SEC with respect to the
Registration Statement.
(d) If at any time prior to the Company Shareholders Meeting,
any event should occur relating to the Company, any Subsidiary, or the
Company's officers or directors that is required to be described in an
amendment or supplement to the definitive Proxy Statement/Prospectus or
the Registration Statement, the Company shall promptly inform Parent.
If at any time prior to the Company Shareholders Meeting, any event
shall occur relating to Parent or Merger Subsidiary or their respective
officers or directors that is required to be described in an amendment
or supplement to the definitive Proxy Statement/Prospectus or the
Registration Statement, Parent shall promptly inform the Company.
Whenever any event occurs that should be described in an amendment of,
or supplement to, the definitive Proxy Statement/Prospectus or the
Registration Statement, the Company or Parent, as the case may be,
shall, upon learning of such event, promptly notify the other and
consult and cooperate with the other in connection with the preparation
of a mutually acceptable amendment or supplement. The parties shall
promptly file such amendment or supplement with the SEC and mail such
amendment or supplement as soon as practicable after it is cleared by
the SEC.
5.5 Consents. The Company will, at its cost and expense, use all
reasonable efforts to obtain all approvals and consents of all third parties
necessary on the part of the Company or its Subsidiaries to consummate the
transactions contemplated hereby. Parent agrees to cooperate with the Company in
connection with obtaining such approvals and consents. Parent will, at its cost
and expense, use all reasonable efforts to obtain all approvals and consents of
all third parties necessary on the part of Parent to consummate the transactions
contemplated hereby. The Company agrees to cooperate with Parent in connection
with obtaining such approvals and consents.
5.6 Affiliates' Letters.
(a) The Company has delivered to Parent a list of names and
addresses of those persons, in the Company's reasonable judgment after
consultation with outside legal counsel, who, as of the date hereof,
are affiliates within the meaning of Rule 145 of the rules and
regulations promulgated under the Securities Act (each such person, an
"Affiliate") of the Company. The Company shall provide Parent such
information and documents as Parent shall reasonably request for
purposes of reviewing such list and shall promptly update such list to
reflect any changes thereto. The Company has caused to be delivered to
Parent an affiliate's letter in the form attached hereto as Exhibit B,
executed by each of the Affiliates of the Company identified in the
foregoing list who were available, and shall use all reasonable efforts
to deliver or cause to be delivered to Parent as soon as practicable
prior to the Effective Time such an affiliate's letter executed by any
Affiliate who was not available to sign and deliver such letter on or
prior to the date hereof and by any additional persons who become
Affiliates after the date hereof. Parent shall be entitled to place
legends as specified in such affiliates' letters on the certificates
evidencing any of the Parent Common Stock to be received by such
Affiliates pursuant to the terms of this Agreement, and to issue
appropriate stop transfer instructions to the transfer agent for the
Parent Common Stock, consistent with the terms of such letters.
(b) For so long as resales of shares of Parent Common Stock
issued pursuant to the Merger are subject to the resale restrictions
set forth in Rule 145 under the Securities Act, Parent will use all
reasonable efforts to comply with Rule 144(c)(1) under the Securities
Act.
5.7 Expenses. Whether or not the Merger is consummated, all costs and
expenses incurred in connection with this Agreement, the transactions
contemplated hereby, the Proxy Statement/Prospectus, and the Registration
Statement will be paid by the party incurring such costs and expenses, except
that the Company and Parent will share equally the cost of printing and filing
with the SEC the Proxy Statement/Prospectus and the Registration Statement, the
filing fees required under the HSR Act or any Foreign Merger Laws, and the fees
charged by PricewaterhouseCoopers LLP for the letters described in Section 5.15
(the "Shared Expenses").
5.8 Further Actions. Subject to the terms and conditions herein
provided and without being required to waive any conditions herein (whether
absolute, discretionary, or otherwise), each of the parties hereto agrees to use
all commercially reasonable efforts to take, or cause to be taken, all action,
and to do, or cause to be done, all things necessary, proper, or advisable to
consummate and make effective the transactions contemplated by this Agreement.
In case at any time after the Effective Time any further action is necessary or
desirable to carry out the purposes of this Agreement, the proper officers and
directors of each party to this Agreement shall take all such necessary action.
5.9 Regulatory Approvals. The Company and Parent will take all
reasonable action as may be necessary under federal or state securities laws or
the HSR Act or Foreign Merger Laws applicable to or necessary for, and will file
as soon as reasonably practicable and, if appropriate, use all reasonable
efforts to have declared effective or approved all documents and notifications
with the SEC and other governmental or regulatory bodies (including, without
limitation, the FDA and equivalent foreign regulatory bodies, and other foreign
regulatory bodies that administer Foreign Merger Laws, and any foreign labor
councils or bodies as may be required) that they deem necessary or appropriate
for, the consummation of the Merger and the transactions contemplated hereby,
and each party shall give the other information reasonably requested by such
other party pertaining to it and its subsidiaries and affiliates to enable such
other party to take such actions. Notwithstanding the foregoing or anything
herein to the contrary, neither Parent nor Merger Subsidiary shall be required
to make arrangements for or to effect the cessation, sale, or other disposition
of particular assets or categories of assets or businesses of Parent, Merger
Subsidiary, the Company, or any of their affiliates.
5.10 Certain Notifications. From time to time prior to the Effective
Time within 5 days of the end of each calendar month, the Company will provide
written notice to the Parent of any matter which, if existing, occurring or
known at the date of this Agreement, would have been required to be set forth or
described in the Disclosure Schedule or which is necessary to correct any
information in the Disclosure Schedule which has been rendered inaccurate
thereby, or (b) would constitute a breach of any covenant contained in this
Agreement. For purposes of determining the accuracy of the representations and
warranties of the Company contained in Article 3 of this Agreement in order to
determine the fulfillment of the conditions set forth in Section 6.2(a) and to
determine whether a breach has occurred for purposes of Section 6.2(b) or
pursuant to Section 7.1(g) hereof, the Disclosure Schedule delivered by Company
in accordance with Section 3.1 shall be deemed to include only the information
contained therein when delivered in accordance with Section 3.1 and shall be
deemed to exclude any information contained in any subsequent notifications
hereunder.
5.11 Voting of Shares. To induce Parent to execute this Agreement,
certain officers and directors of the Company have executed and delivered as of
the date hereof (and prior to the Company's execution and delivery of the Stock
Option Agreement described in Section 5.17 below) Agreements to Facilitate
Merger in the form attached hereto as Exhibit C, pursuant to which each such
person has agreed to vote his or her shares of Company Common Stock in favor of
the Merger at the Company Shareholders Meeting. At the request of Parent, after
the execution of this Agreement the Company will use all reasonable efforts to
have other officers and directors of the Company also execute Agreements to
Facilitate Merger.
5.12 Noncompetition Agreements. To induce Parent to execute this
Agreement, the Company has caused Anthony Badolato and Allan Seck to execute and
deliver to Parent as of the date hereof (but expressly contingent upon the
Closing of the Merger), noncompetition agreements substantially in the form of
Exhibit D hereto each with a term of 42 months from the Effective Time, and the
Company shall use all reasonable efforts to cause Gregory Melsen, William
Haworth and Bradley Goskowicz to execute and deliver to Parent within 30 days of
the date hereof (but expressly contingent upon the Closing of the Merger)
noncompetition agreements substantially in the form of Exhibit D hereto each
with a term of 24 months from the Effective Time.
5.13 NYSE Listing Application. Parent shall prepare and submit to the
NYSE a listing application for the Parent Common Stock to be issued in the
Merger pursuant to Article 1 of this Agreement. The Company shall cooperate with
Parent in such listing application.
5.14 Indemnification. Parent agrees that it will, after the Effective
Time, provide to those individuals who have served as directors or officers of
the Company or its Subsidiaries indemnification equivalent to that provided by
the Articles of Incorporation and Bylaws of the Company with respect to matters
occurring prior to the Effective Time, including without limitation the
authorization of this Agreement and the transactions contemplated hereby, for a
period of six years from the Effective Time (or, in the case of matters
occurring prior to the Effective Time which, have not been resolved prior to the
sixth anniversary, until such matters are finally resolved). To the extent
permitted by law, Parent will advance expenses in connection with the foregoing
indemnification. In the event the Surviving Corporation or any of its successors
or assigns (i) consolidates with or merges into any other person and the
Surviving Corporation shall not be the continuing or surviving corporation or
entity of such consolidation or merger or (ii) transfers all or substantially
all of its properties and assets to any person, then, and in each such case,
proper provision shall be made so that the successors and assigns of the
Surviving Corporation shall assume the obligations set forth in this Section
5.14. For a period of six years after the Effective Time, Parent will provide
that portion of directors' and officers' liability insurance that serves to
reimburse officers and directors of the Company and its Subsidiaries with
respect to claims against such officers and directors arising from facts or
events that occurred before the Effective Time of at least the same coverage and
amounts, and containing terms and conditions no less advantageous, as that
coverage currently provided by the Company and its Subsidiaries.
5.15 [Intentionally omitted]
5.16 Subsidiary Shares. At or prior to the Closing, the Company shall
cause all issued and outstanding Subsidiary shares owned by any person other
than the Company to be transferred for no or nominal consideration to such
person or persons designated by Parent.
5.17 Stock Option Agreement. To induce Parent to execute this
Agreement, the Company has executed and delivered to Parent as of the date
hereof (and after the execution and delivery of certain Agreements to Facilitate
Merger described in Section 5.11 above) a Stock Option Agreement in the form
attached hereto as Exhibit E, pursuant to which the Company has granted to
Parent an option to acquire from the Company such number of shares of Company
Common Stock as equals 19.9% of the aggregate number of outstanding shares of
Company Common Stock, at an exercise price equal to $11.125 per share or such
lesser amount as is described in the second paragraph of Section 1.3(a) hereof.
Such option shall become exercisable only in the events described in the Stock
Option Agreement.
5.18 Benefit Plans and Employee Matters. From and after the Effective
Time, Parent shall to the extent practicable cause the Surviving Corporation to
provide employee benefits and programs to the Company's employees that, in the
aggregate, are substantially comparable or more favorable than those in
existence as of the date hereof and disclosed in writing to Parent prior to the
date hereof.
5.19 Tax. Parent agrees that it will not knowingly take any action that
would have the effect of jeopardizing the qualification of the Merger as a
reorganization within the meaning of Section 368(a)(2)(E) of the Code.
ARTICLE 6
CLOSING CONDITIONS
6.1 Conditions to Obligations of Parent, Merger Subsidiary, and the
Company. The respective obligations of each party to consummate the Merger shall
be subject to the fulfillment at or prior to the Closing of the following
conditions:
(a) No Injunction. None of Parent, Merger Subsidiary, or the
Company shall be subject to any final order, decree, or injunction of a
court of competent jurisdiction within the United States that (i)
prevents or materially delays the consummation of the Merger, or (ii)
would impose any material limitation on the ability of Parent
effectively to exercise full rights of ownership of the Company or the
assets or business of the Company.
(b) Shareholder Approval. The approval of the shareholders of
the Company referred to in Section 5.4 hereof shall have been obtained,
in accordance with the MBCA and the Company's Articles of Incorporation
and Bylaws.
(c) Registration Statement. The Registration Statement (as
amended or supplemented) shall have become effective under the 1933 Act
and shall not be subject to any "stop order," and no action, suit,
proceeding, or investigation by the SEC to suspend the effectiveness or
qualification thereof shall have been initiated and be continuing or
have been threatened and be unresolved. Parent shall also have received
all state securities law or blue sky authorizations necessary to carry
out the transactions contemplated hereby.
(d) NYSE Listing. The shares of Parent Common Stock to be
delivered pursuant to the Merger shall have been duly listed on the
NYSE, subject to official notice of issuance.
(e) Waiting Periods. The waiting periods applicable to the
consummation of the Merger under the HSR Act and any Foreign Merger
Laws shall have expired or been terminated.
6.2 Conditions to Obligations of Parent and Merger Subsidiary. The
respective obligations of Parent and Merger Subsidiary to consummate the Merger
shall be subject to the fulfillment at or prior to the Closing of the following
additional conditions:
(a) Representations and Warranties True. Each representation
and warranty of the Company contained in this Agreement, without regard
to any qualification or reference to immateriality or "Company Material
Adverse Effect," shall be true and correct on the date hereof and on
the Closing Date as though such representations and warranties were
made on such date (except those representations and warranties that
address matters only as of a particular date shall remain true and
correct as of such date), except for any inaccuracies that,
individually or in the aggregate, have not had, and would not have, a
Company Material Adverse Effect.
(b) Performance. The Company shall have performed and complied
in all material respects with all agreements, obligations, and
conditions required by this Agreement to be performed or complied with
by it on or prior to the Closing, and Parent shall have received a
certificate to such effect signed by the Chief Executive Officer of the
Company.
(c) Consents. The Company shall have obtained all permits,
authorizations, consents, and approvals required on its part to perform
its obligations under, and consummate the transactions contemplated by,
this Agreement, in form and substance reasonably satisfactory to
Parent, and Parent and Merger Subsidiary shall have received evidence
reasonably satisfactory to them of the receipt of such permits,
authorizations, consents, and approvals.
(d) Opinion of Counsel for the Company. Parent and Merger
Subsidiary shall have received an opinion of Oppenheimer Wolff &
Donnelly LLP, counsel to the Company, dated the Closing Date, in form
and substance reasonably satisfactory to Parent, to the effect set
forth in Exhibit F hereto.
(e) Affiliates' Letters. Parent shall have received a letter
from each of the Affiliates pursuant to Section 5.6 hereof.
(f) Noncompetition Agreements. Parent shall have received
executed agreements from such persons, and in such form satisfactory to
Parent, as described in Section 5.12 hereof.
(g) Resignations. Such officers and directors of the Company
or of any Subsidiary as shall have been specified Parent shall have
tendered their respective resignations effective as of the Effective
Time.
(h) [Intentionally omitted]
(i) Continued Employment of CEO. The chief executive officer
of the Company shall have agreed to continue his employment with the
Company following the Merger on such terms as are mutually satisfactory
to Parent and such officer.
(j) Subsidiary Shares. The transfer of Subsidiary shares as
provided in Section 5.16 shall have occurred.
6.3 Conditions to Obligations of the Company. The obligation of the
Company to consummate the Merger shall be subject to the fulfillment at or prior
to the Closing of the following additional conditions:
(a) Representations and Warranties True. Each representation
and warranty of Parent contained in this Agreement, without regard to
any qualification or reference to immateriality or "Parent Material
Adverse Effect," shall be true and correct on the date of this
Agreement and on the Closing Date as though such representations and
warranties were made on such date (except those representations and
warranties that address matters only as of a particular date shall
remain true and correct as of such date), except for any inaccuracies
that, individually or in the aggregate, have not had, and would not
have, a Parent Material Adverse Effect.
(b) Performance. Parent and Merger Subsidiary shall have
performed and complied in all material respects with all agreements,
obligations, and conditions required by this Agreement to be performed
or complied with by them on or prior to the Closing.
(c) Consents. Parent and Merger Subsidiary shall have obtained
all permits, authorizations, consents, and approvals required on their
part to perform their obligations under, and consummate the
transactions contemplated by, this Agreement, in form and substance
satisfactory to the Company, and the Company shall have received
evidence satisfactory to it of the receipt of such permits,
authorizations, consents, and approvals.
(d) Opinion of Counsel for Parent. The Company shall have
received an opinion of Fredrikson & Byron, P.A., counsel to Parent,
dated the Closing Date, in form and substance reasonably satisfactory
to the Company, to the effect set forth in Exhibit G hereto.
(e) Tax Opinion. The Company shall have received an opinion of
Oppenheimer Wolff & Donnelly LLP, counsel to the Company, to the effect
that, subject to customary conditions and representations, the Merger
will be treated for federal income tax purposes as a reorganization
within the meaning of Section 368(a)(2)(E) of the Code. This condition
shall be deemed waived in the event that such tax opinion is not
rendered because the Company or its shareholders have failed to provide
such customary representations.
ARTICLE 7
TERMINATION AND ABANDONMENT
7.1 Termination. This Agreement may be terminated at any time prior to
the Effective Time, whether before or after approval by the shareholders of the
Company, only:
(a) by mutual written consent duly authorized by the Board of
Directors of Parent and the Board of Directors of the Company;
(b) by either Parent or the Company if the Merger shall not
have been consummated on or before the date that is six months after
the date hereof; provided, however, that the terminating party shall
not have breached in any material respect its obligations under this
Agreement in any manner that shall have been the proximate cause of, or
resulted in, the failure to consummate the Merger by such date and
provided further, however, that, if a request for additional
information is received from the U.S. Federal Trade Commission ("FTC")
or Department of Justice ("DOJ") pursuant to the HSR Act or additional
information is requested by an authority (a "Foreign Authority")
pursuant to Foreign Merger Laws, such date shall be extended to the
90th day following acknowledgment by the FTC, DOJ, or Foreign
Authority, as applicable, that Parent and the Company have complied
with such request, but in any event not later than nine months from the
date hereof;
(c) by either Parent or the Company if a court of competent
jurisdiction or an administrative, governmental, or regulatory
authority has issued a final nonappealable order, decree, or ruling, or
taken any other action, having the effect of permanently restraining,
enjoining, or otherwise prohibiting the Merger;
(d) by either Parent or the Company if, at the Company
Shareholders Meeting, the requisite vote of the shareholders of the
Company is not obtained, except that the right to terminate this
Agreement under this Section 7.1(d) will not be available to any party
whose failure to perform any material obligation under this Agreement
has been the proximate cause of, or resulted in, the failure to obtain
the requisite vote of the shareholders of the Company;
(e) by Parent if either (i) the Company has breached its
obligations under Section 5.2 in any material respect, (ii) the Board
of Directors of the Company has recommended, approved, accepted, or
entered into an agreement regarding, an Alternative Proposal, as
defined in Section 5.2, (iii) the Board of Directors of the Company has
withdrawn or modified in a manner adverse to Parent its recommendation
of the Merger, or (iv) a tender offer or exchange offer for 15% or more
of the outstanding shares of Company Common Stock is commenced, and the
Board of Directors of the Company, within 10 business days after such
tender offer or exchange offer is so commenced, either fails to
recommend against acceptance of such tender offer or exchange offer by
its shareholders or takes no position with respect to the acceptance of
such tender offer or exchange offer by its shareholders;
(f) by the Company if (i) it is not in material breach of its
obligations under Section 5.2, (ii) the Board of Directors of the
Company has authorized acceptance of an Alternative Proposal, and (iii)
the Company has paid to Parent the fee required by Section 7.2 to be
paid to Parent in the manner therein provided;
(g) by Parent if (i) Parent is not in material breach of its
obligations under this Agreement and (ii) there has been a material
breach by the Company of any of its representations, warranties, or
obligations under this Agreement of by an Affiliate of the Company
under such person's affiliate's letter described in Section 5.6 or by
an officer or director of the Company under such person's Agreement to
Facilitate Merger described in Section 5.11 such that the conditions in
Section 6.2 will not be satisfied, and the breach is not curable or, if
curable, is not cured by the Company within 30 calendar days after
receipt by the Company of written notice from Parent of such breach;
(h) by the Company if (i) the Company is not in material
breach of its obligations under this Agreement and (ii) there has been
a material breach by Parent of any of its representations, warranties,
or obligations under this Agreement such that the conditions in Section
6.3 will not be satisfied, and the breach is not curable or, if
curable, is not cured by Parent within 30 calendar days after receipt
by Parent of written notice from the Company of such breach.
(i) by Parent if, within 10 business days following receipt of
the Disclosure Schedule as described in Section 3.1, Parent determines
that the Disclosure Schedule contains information which in Parent's
good faith, reasonable business judgment adversely affects the value of
the Company's business or prospects.
7.2 Effect of Termination.
(a) In recognition of the time, efforts, and expenses expended
and incurred by Parent with respect to the Company and the opportunity
that the acquisition of the Company presents to Parent, if:
(i) this Agreement is terminated pursuant to Section
7.1(e) or 7.1(f); or
(ii) any third party makes an Alternative Proposal to
which the Company has made a response or any third party
acquires 15% or more of the outstanding Company Common Stock
prior to the Company Shareholders Meeting, and either (A) the
requisite vote of the shareholders of the Company to approve
the Merger is not obtained or (B) this Agreement is terminated
pursuant to Section 7.1(g) where the Company's breach is
willful and intentional or is terminated pursuant to Section
7.1(d),
then, in any such event, the Company will pay to Parent, upon the
termination date in the event of termination pursuant to Section
7.1(f), and immediately upon the date of entering into an agreement
providing for an Alternative Proposal (if such agreement is entered
into within 12 months of the termination of this Agreement), in the
case of a termination pursuant to Section 7.1(e) or in the case of the
events specified in clause (ii) above (by wire transfer of immediately
available funds to an account designated by Parent for such purpose), a
fee equal to $2.75 million. The Company acknowledges that the
agreements contained in this Section 7.2 are an integral part of the
transactions contemplated by this Agreement and are not a penalty, and
that, without these agreements, Parent would not enter into this
Agreement. If the Company fails to pay promptly the fee due pursuant to
this Section 7.2, the Company shall also pay to Parent Parent's costs
and expenses (including legal fees and expenses) in connection with any
action, including the filing of any lawsuit or other legal action,
taken to collect payment, together with interest on the amount of the
unpaid fee under this section, accruing from its due date, at an
interest rate per annum equal to two percentage points in excess of the
prime commercial lending rate quoted by Norwest Bank Minnesota, N.A.
Any change in the interest rate hereunder resulting from a change in
such prime rate shall be effective at the beginning of the day of such
change in such prime rate.
(b) Except as provided in the next sentence of this paragraph,
in the event of the termination of this Agreement pursuant to any
paragraph of Section 7.1, the obligations of the parties to consummate
the Merger will expire, and none of the parties will have any further
obligations under this Agreement except pursuant to Sections 5.3, 5.7,
and 7.2(a) and which shall survive termination of this Agreement. In
the event of the termination of this Agreement pursuant to any
paragraph of Section 7.1 that is caused by a breach of a party, the
party whose breach was the basis for the termination will not be
relieved from any liability for its breach or its obligations pursuant
to Section 7.2(a), and the other party will have no further obligations
under this Agreement except as provided in Sections 5.3 and 5.7 and
Article 8.
ARTICLE 8
MISCELLANEOUS
8.1 Amendment and Modification. Subject to applicable law, this
Agreement may be amended, modified, or supplemented only by written agreement of
Parent, Merger Subsidiary, and the Company at any time prior to the Effective
Time with respect to any of the terms contained herein. This Agreement may not
be amended except by an instrument in writing signed on behalf of each of the
parties hereto.
8.2 Waiver of Compliance; Consents. Any failure of Parent or Merger
Subsidiary on the one hand, or the Company on the other hand, to comply with any
obligation, covenant, agreement, or condition herein may be waived by the
Company or Parent, respectively, only by a written instrument signed by an
officer of the party granting such waiver, but such waiver or failure to insist
upon strict compliance with such obligation, covenant, agreement, or condition
shall not operate as a waiver of, or estoppel with respect to, any subsequent or
other failure. Whenever this Agreement requires or permits consent by or on
behalf of any party hereto, such consent shall be given in writing. Merger
Subsidiary agrees that any consent or waiver of compliance given by Parent
hereunder shall be conclusively binding upon Merger Subsidiary, whether or not
given expressly on its behalf.
8.3 Investigation; Survival of Representations and Warranties. The
respective representations and warranties of Parent and the Company contained
herein or in any certificates or other documents delivered prior to or at the
Closing shall not be deemed waived or otherwise affected by any investigation
made by any party hereto. Each and every representation and warranty contained
herein shall be deemed to be conditions to the Merger and shall not survive the
Merger. This Section 8.3 shall have no effect upon any other obligation of the
parties hereto, whether to be performed before or after the Closing. Parent
acknowledges and agrees that (i) other than the representations and warranties
of the Company and its Subsidiaries specifically contained in this Agreement,
including for this purpose the Disclosure Schedule and other matters referred to
in this Agreement or the Disclosure Schedule, there are no representations or
warranties of the Company or its Subsidiaries either expressed or implied with
respect to the Company, its Subsidiaries or their respective assets, liabilities
and businesses, and (ii) other than as incorporated, referred to or repeated in
the representations and warranties of the Company made in this Agreement or in
the Disclosure Schedule, it shall have no claim or right to indemnification with
respect to any information (whether written or oral), documents or material
furnished by the Company, its Subsidiaries or any of their respective officers,
directors, employees, agents or advisors to Parent, including any information,
documents or material made available to Parent in certain "data rooms,"
management presentations or any other form in expectation of the transactions
contemplated by this Agreement
8.4 Notices. All notices and other communications hereunder shall be in
writing and shall be deemed given when delivered personally by commercial
courier service or otherwise, or by telecopier, or three days after such notice
is mailed by registered or certified mail (return receipt requested) to the
parties at the following addresses (or at such other address for a party as
shall be specified by like notice):
(a) if to Parent or Merger Subsidiary, to it at:
Medtronic, Inc.
7000 Central Avenue, N.E.
Minneapolis, MN 55432
with separate copies thereof addressed to
Attention: General Counsel
FAX: (612) 572-5459
and
Attention: Vice President and Chief Development Officer
FAX: (612) 572-5404
(b) If to the Company, to it at:
AVECOR Cardiovascular, Inc.
7611 Northland Drive
Minneapolis, MN 55428
FAX: (612) 391-9020
Attention: Anthony Badolato, CEO
with a copy to:
Oppenheimer Wolff & Donnelly LLP
Plaza VII Building, Suite 3400
45 South Seventh Street
Minneapolis, MN 55402
FAX: (612) 607-7100
Attention: Richard Lareau
8.5 Assignment. This Agreement and all of the provisions hereof shall
be binding upon and inure to the benefit of the parties hereto and their
respective successors and permitted assigns, but neither this Agreement nor any
of the rights, interests, or obligations hereunder shall be assigned by any of
the parties hereto without the prior written consent of the other parties, nor
is this Agreement intended to confer upon any other person except the parties
hereto any rights or remedies hereunder, except that Section 5.14 of this
Agreement shall inure to the benefit of the persons identified therein.
8.6 Governing Law. This Agreement shall be governed by, construed and
enforced in accordance with the laws of the State of Minnesota (regardless of
the laws that might otherwise govern under applicable Minnesota principles of
conflicts of law).
8.7 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original, and all of which
together shall constitute one and the same instrument.
8.8 Knowledge. As used in this Agreement or the instruments,
certificates or other documents required hereunder, the term "knowledge" of an
entity shall mean knowledge actually possessed by any director or officer of
such entity.
8.9 Interpretation. The Table of Contents, article and section headings
contained in this Agreement are inserted for reference purposes only and shall
not affect the meaning or interpretation of this Agreement. This Agreement shall
be construed without regard to any presumption or other rule requiring the
resolution of any ambiguity regarding the interpretation or construction hereof
against the party causing this Agreement to be drafted.
8.10 Publicity. Upon execution of this Agreement by Parent, Merger
Subsidiary, and the Company, the parties shall jointly issue a press release, as
agreed upon by them. The parties intend that all future statements or
communications to the public or press regarding this Agreement or the Merger
will be mutually agreed upon by them and neither party shall, without such
mutual agreement or the prior consent of the other, issue any statement or
communication to the public or to the press regarding this Agreement, or any of
the terms, conditions, or other matters with respect to this Agreement, except
as required by law or the rules of the NYSE or Nasdaq and then only (a) upon the
advice of such party's legal counsel; (b) to the extent required by law or the
rules of the NYSE or Nasdaq; and (c) following prior notice to the other party
and an opportunity for the other party to discuss with the disclosing party
(which notice shall include a copy of the proposed statement or communication to
be issued to the press or public). The foregoing shall not restrict Parent's or
the Company's communications with their employees or customers in the ordinary
course of business.
8.11 Entire Agreement. This Agreement, including the exhibits and
schedules hereto and the Confidentiality Agreement referred to herein, embodies
the entire agreement and understanding of the parties hereto in respect of the
subject matter contained herein. This Agreement and the Confidentiality
Agreement supersede all prior agreements and the understandings between the
parties with respect to such subject matter. No discussions regarding or
exchange of drafts or comments in connection with the transactions contemplated
herein shall constitute an agreement among the parties hereto. Any agreement
among the parties shall exist only when the parties have fully executed and
delivered this Agreement.
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first above written.
MEDTRONIC, INC.
By /s/ Michael D. Ellwein
Its: Vice President
AC MERGER CORP.
By /s/ Michael D. Ellwein
Its: President
AVECOR CARDIOVASCULAR, INC.
By /s/ Anthony Badolato
Its: CEO
